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CHAPTER I: Introduction 
In the liver, lipid content is regulated by dietary FA (FA) or carbohydrate 
uptake, as well as hepatic biosynthesis, esterification, oxidation, and export of FA (1, 
2). After consumption, dietary carbohydrates are both used for normal functions and, 
if present in excess, stored for later use. Enzymes involved in glycolytic and lipogenic 
pathways are dynamically regulated at both transcriptional and post-translational 
levels by various factors such as substrate concentrations and hormones (3). 
Metabolic signals, such as an excess of FA, glucose, or insulin, can regulate the 
activity or abundance of key transcription factors to modulate hepatic lipid metabolism 
(1). Many liver-specific transcription factors have been identified as prospective 
targets for de novo lipogenesis and FA oxidation, including sterol regulatory element 
binding protein-1c (SREBP-1c) , peroxisome proliferator-activated receptors 
(PPARs), liver X receptor (LXRα), and carbohydrate-responsive element-binding 
protein (ChREBP) (4-7). These factors integrate signals from multiple pathways and 
organize the activity of the metabolic enzymes necessary for hepatic lipid metabolism 
with the supply of energy and FA. Cyclic-AMP response element binding protein H 
(CREBH) is an endoplasmic reticulum (ER)-membrane-bound transcription factor that 
is preferentially expressed in liver (8-10). CREBH is a major player in regulating lipid 
and glucose metabolism in the liver. Metabolism of these two classes of molecules is 
important in maintaining energy production, usage and storage in individual cells as 
well as maintaining energy homeostasis at the systemic level(11, 12). Disturbances 
to this delicate balance may lead to energy imbalances and serious health 
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consequences, particularly non-alcoholic fatty liver disease (NAFLD) or non-alcoholic 
steatohepatitis (11-13). 
1.1 Hepatic Energy Metabolism 
Hepatocytes, the parenchymal cell of the liver, exhibit a unique strategies for 
processing metabolites (13-18). Hepatocytes carry out multiple metabolic processes 
including glycolysis, gluconeogenesis, lipolysis, lipogenesis, FA oxidation, and 
ketogenesis (Figure 1). Glycolysis is the breakdown of glucose to pyruvate, which is 
carried out in ten steps (19). During glycolysis, the conversion of glucose to glucose-
6-phosphate, the conversion of fructose-6-phosphate to fructose-1,6-bisphosphate 
and the conversion of phosphoenolpyruvate (PEP) to pyruvate, are regulated by the 
enzymes glucokinase, phosphofructokinase, and pyruvate kinase, respectively. The 
end product of glycolysis, pyruvate, can be irreversibly converted to acetyl coenzyme 
A (acetyl CoA), a metabolite involved in multiple metabolic pathways (20). 
 
Figure 1. Simplified model of energy metabolism. Glucose taken from blood enters 
the glycolytic pathway to generate pyruvate and glycogen. Glucose may be 
generated by the gluconeogenesis or glycogenolysis. Acetyl CoA may convert 
between ketone bodies or triglycerides. Acetyl CoA also may generate ATP via the 
TCA cycle and oxidative phosphorylation (not shown). 
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Gluconeogenesis is the production of glucose from non-sugar sources (19, 
21). The source used may be lactate, pyruvate, or amino acids. Hepatocytes utilize 
lactate produced in peripheral tissues via anaerobic respiration. The multistep 
process of gluconeogenesis is regulated by four enzymes: glucose-6-phosphatase, 
fructose-1,6-bisphosphatase, pyruvate carboxylase, and PEP carboxykinase 
(PEPCK). Interestingly, the rate of activity of both glucose-6-phosphatase and 
PEPCK are primarily regulated at the transcriptional level. Glucose can also be 
stored as or generated from glycogen, a polysaccharide that consists of branched 
chains of glucose molecules (22). These chains can be quickly broken down to 
produce glucose that can enter the bloodstream or the glycolytic pathway. The 
breakdown of glycogen, known as glycogenolysis, is regulated by the 
phosphorylation of its rate-limiting enzyme, glycogen phosphorylase (22). Excess 
levels of glucose are stored as glycogen via the glycogen synthesis pathway. This 
pathway is regulated by phosphorylation of the glycogen synthase enzyme. 
In addition to its involvement in the glucose metabolism, pyruvate also can be 
converted irreversibly to acetyl-CoA by the pyruvate dehydrogenase complex (23). 
Acetyl-CoA is a predecessor metabolite of both lipid and ketone body production. 
Increased levels of acetyl-CoA increase lipogenesis. Activation of the enzyme, acetyl-
CoA carboxylase, induces the conversion of acetyl-CoA to malonyl-CoA which is then 
converted to malonyl-ACP and shuttled into the mitochondria. Through multiple 
conversion processes, the malonyl-ACP molecules are condensed to produce a FA 
chain (24). FA chains are joined to a glycerol-3-phosphate back bone to form a 
triglyceride (TG). After a TG is formed, it may be stored in cytoplasmic lipid droplets 
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or incorporated into VLDL particles and secreted into the blood. Additionally, in a 
state of energetic need, TG can also be hydrolyzed to release the esterified FA. 
These FA are destined to undergo oxidation. Conversion of carbohydrates to TG 
involves two steps: glycolysis which generates acetyl-CoA from glucose, and 
lipogenesis which converts acetyl-CoA to FA. 
Retrieving energy from TG requires hydrolysis of the TG molecule to yield the 
stored FA. Lipolysis occurs in three steps, each of which releases one FA chain (25). 
First, the TG is cleaved to produce one FA chain and a diacylglyceride. Next, the 
diacylglyceride is cleaved to produce another FA and a monoacylglyceride. The final 
step is the cleavage of the last FA chain and a glycerol molecule. Glycerol can be 
converted to dihydroxyacetone phosphate to feed into the glycolytic and 
gluconeogenic pathways. TG carried by lipoproteins must also undergo lipolysis to 
release FA which can be taken up by the target cells. After free FA have been 
released from the TG, they undergo oxidation (26). The primary method of FA 
oxidation is mitochondrial β-oxidation. FA oxidation is a primary source of energy 
during fasting. Oxidation of FA yields acetyl-CoA. FA that cross the plasma 
membrane are rapidly converted to fatty acyl-CoA. This process is known as FA 
activation.  
Ketogenesis is the process by which acetyl-CoA is used to generate ketone 
bodies (27, 28). Ketone bodies are metabolites that can be converted to energy by 
converting them back to acetyl-CoA. Ketogenesis occurs mainly in the liver during 
prolonged states of fasting, when available blood glucose levels are low. During 
fasting, ketones generated in the liver are used as energy in peripheral tissues, 
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especially the brain which cannot produce energy from FA oxidation. Insulin signaling 
represses ketogenesis. There are three types of ketone bodies: acetoacetone, 
acetone, and 3-hydroxybutyric acid (BOH). The rate of conversion from acetyl-CoA to 
these ketone bodies is limited by the enzyme HMG-CoA synthase, which converts 
acetoacetyl-CoA to HMG-CoA. The first ketone body that can be formed from acetyl-
CoA is acetoacetate. Acetoacetate can generate acetone by non-enzymatic 
decarboxylation. Acetoacetate can also generate BOH in a reaction catalyzed by the 
enzyme D-β-hydroxybutryate dehydrogenase (BDH1). Typically, during long-term 
fasting, BOH is the most abundant ketone body in serum (29, 30). 
1.2 Hepatic Energy Maintenance 
The liver is an organ that is heavily involved in energy homeostasis. The liver 
monitors and maintains metabolite levels through complex regulatory mechanisms. 
Hormones, such as insulin and glucagon, induce signaling pathways in hepatocytes 
that lead to altered metabolic profiles. Insulin signaling decreases blood sugar, while 
up-regulating glycolysis, glycogenesis, and lipid storage (31). Binding of insulin to the 
insulin receptor induces autophosphorylation and activation of the receptor. Activation 
of this transmembrane receptor induces recruitment, phosphorylation and activation 
of insulin receptor substrate (IRS) proteins. Active IRS1 and IRS2 initiate a signaling 
cascade that induces glucose receptor transport from the Golgi apparatus to the cell 
membrane to increase glucose uptake. Additionally, the IRS substrates activate PI3 
kinase and, consequently, protein kinase B (AKT). AKT induces both glycogen 
synthesis and lipid storage (Figure 2).  
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Glucagon is another metabolic hormone that is produced in the pancreas (32). 
Production of glucagon is induced by fasting conditions leading to decreased levels of 
blood glucose. Glucagon is released into the bloodstream where it interacts with 
hepatic receptors. Hepatocytes under the regulation of glucagon exhibit upregulated 
gluconeogenesis and glycogenolysis resulting in increased blood glucose. 
Additionally, both lipolysis and ketogenesis are upregulated in hepatocytes under 
glucagon signaling (33, 34).  
 
 
Figure 2. Diagram of insulin signaling in the hepatocyte. Insulin activates insulin 
receptors (IR), initiating a signaling cascade resulting in increased glucose uptake via 
the Glucose transporter (GLUT), lipogenesis and glycogen storage, as well as 
decreased gluconeogenesis.  
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Glucagon signaling functions through activation of the glucagon receptor, a G-
protein coupled receptor. Activation of this receptor results in recruitment of GTP to 
the associated G-protein complex. This allows the alpha subunit of the G-protein 
complex to dissociate from the beta and gamma subunits and activate adenylate 
cyclase. Adenylate cyclase is an enzyme that converts ATP to cyclic AMP (cAMP). 
Increased intracellular levels of cAMP result in activation of protein kinase A (PKA). 
Active PKA initiates multiple signaling cascades, including activation of the CREB 
transcription factor and phosphorylase kinase. Targets of CREB transcriptional 
regulation include Pepck and G6pc, two major players in the gluconeogenic pathway. 
Phosphorylase kinase induces signaling cascades that both induce glycogenolysis 
and inhibit glycogen synthesis. 
In contrast to incoming hormone signals, the liver is also responsible for 
producing hormones that deliver signals on the systemic level, as well as, to specific 
peripheral organs. These liver-derived hormones include hepcidin, betatrophin, and 
fibroblast growth factor 21 (FGF21) (35-37). Hepcidin is a powerful regulator of iron 
concentration. FGF21 is a systemic regulator of energy metabolism. Hepcidin and 
FGF21 are systemic regulators, while betatrophin acts as a blood lipid regulator by 
regulating serum TG levels, possibly through promoting ANGPTL3 cleavage (38). 
1.3 Transcriptional Regulators of Hepatic Energy Metabolism 
 Hepatic energy metabolism is often regulated at the transcriptional level by 
modulating transcription of mRNAs of key rate-limiting enzymes. This regulation can 
be observed in various pathways, including gluconeogenesis, lipolysis, lipogenesis, 
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FA metabolism, and ketogenesis. Metabolic stress, in the form of hormone signaling 
or altered metabolite levels, can trigger these changes. 
 The rate of gluconeogenesis is regulated by activity of two enzymes, PEPCK 
and G6PC, the catalytic subunit of the glucose-6-phosphatase enzyme complex (21). 
Both Pepck and G6pc contain segments of DNA known as insulin response elements 
in their promoter regions. This element allows the transcription factor, FOXO1, to bind 
and increase the transcriptional rate of these genes. AKT phosphorylation, induced 
by the insulin signaling cascade, results in increased AKT activity. AKT irreversibly 
phosphorylates FOXO1 on the promoter region of the gluconeogenic genes, causing 
FOXO1 to dissociate from the DNA and exit the nucleus. This causes a decrease in 
transcription of both Pepck and G6pc, and subsequently, inhibits gluconeogenesis 
(Figure 2). 
FA metabolism is the avenue by which cells maintain homeostasis of FA levels 
by way of oxidation and synthesis of FA. The balance of these opposing processes is 
maintained by transcriptional regulation of key enzymes and activation of pertinent 
transcription factors. Dietary intake of lipid metabolites is a major factor in regulating 
the expression and activation of these proteins. The peroxisome proliferator-
activating receptor (PPAR) family, liver x receptor alpha (LXRα), carbohydrate 
response element binding factor (ChREBP), and sterol response element-binding 
protein 1c (SREBP1c) are integral transcription factors in the maintaining FA 
homeostasis (39).  
PPAR family members PPARα is a nuclear receptor that is important in the 
maintenance of lipid homeostasis. PPARα activity in the liver can be induced by 
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fasting or influx of dietary lipids (40, 41). This allows PPARα to act as a FA sensor 
and induce FA oxidation (42). Transcriptional targets of PPARα include, 
apolipoproteins, which are involved in lipolysis, and carnitine palmitoyl-transferases, 
which are involved in FA oxidation (43-46). Additionally, PPARα-null mice display a 
defective fasting response characterized by low ketone and glucose levels in blood 
(45).  
LXRα is an isoform of LXR that is highly expressed in liver tissue. LXRα is a 
key regulator of hepatic lipogenesis and is induced by FA (47, 48). Lxrα-null mice 
demonstrate defective in FA synthesis and lipogenesis, coinciding with down-
regulation of the Srebp-1, stearoyl CoA desaturase-1 (Scd1), and FA synthase (Fasn) 
genes (49). SREPB1c is a transcription factor that targets genes involved in de novo 
lipogenesis. Unlike SREBP1a, another SREBP1 isoform, SREBP1c is not regulated 
by intracellular sterol concentration. Instead SREBP1c regulation is controlled by 
insulin signaling (50). SREBP1c targets genes required for glycolysis and lipogenesis 
(51). Upon activation, the ER-membrane bound SREBP1c protein migrates to the 
Golgi and is cleaved, releasing the active cytosolic portion of the protein which acts 
as a transcription factor (52). ChREBP is a transcription factor that is activated in 
response to glucose (53). Upon activation, ChREBP induces lipogenesis by up-
regulating Scd1, Fasn, and acetyl-CoA carboxylase 1 (54, 55). Knockdown of 
ChREBP in ob/ob mice resulted in reduced hepatic steatosis and increased insulin 
sensitivity (56).  
1.4 Non-alcoholic fatty liver disease (NAFLD) 
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The above-mentioned methods of regulation describe a delicate balancing act 
that relies on proper function in all metabolic pathways to maintain homeostasis. 
Imbalances in hepatic energy metabolism result in disruption of this homeostasis. If 
the disruption results in excess lipid accumulation in the liver, NAFLD can occur.  
NAFLD is defined by hepatic steatosis in an individual who does not excessively 
consume alcohol (57). Inhibition or deletion of some genes involved in lipid 
metabolism can protect against development of NAFLD (58). For example, the Scd1-
null mouse model is resistant to diet-induced hepatic steatosis (59). Prolonged or 
harmful disruptions may result in NAFLD, a disease state in the liver defined by an 
excessive accumulation of fat. NAFLD places an individual at risk for NASH, a more 
advanced form of liver disease that involves both steatosis and inflammation of the 
liver. 
NASH develops as a progression of NAFLD. The progression of a healthy liver 
to NAFLD to NASH is described by the two-hit model (60) (Figure 3). NAFLD is the 
result of TG buildup in the liver. This buildup is caused by an inability of the liver to 
balance import and synthesis of TG with the export and degradation or TG. The 
imbalance is the first hit and is often a result of increased lipid delivery to the liver, 
increased hepatic de novo lipogenesis, or insulin resistance. After the first hit, a liver 
that has NAFLD is susceptible to a second hit. The second hit is a stress-inducing 
factor that results in inflammation. These factors include oxidative stress, endotoxins, 
saturated FA, or inflammatory cytokines (61, 62). Healthy livers are resistant to 
second hits, but livers with NAFLD are at higher risk for liver damage caused by 
second hit exposure. 
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Figure 3. Illustration of the two-hit model of NASH pathology. 
 
NAFLD does not always present with symptoms, but NAFLD patients do 
commonly suffer from fatigue (63). Additionally, NAFLD often presents with insulin 
resistance (64). Patients with NAFLD present altered liver enzyme levels, particularly 
those of aspartate transaminase (AST) and alanine transaminase (ALT). In healthy 
individuals, the ratio of AST to ALT is less than one. Upon the onset of NAFLD, that 
ratio increases (57, 65). Patients with NASH often present with an AST to ALT ratio 
that is higher than one, but a proper diagnosis of NASH must be made by liver biopsy 
(66, 67). 
1.5 CREBH 
The ER is an organelle that is heavily involved in protein folding and plays an 
important role in stress response (68). The ER membrane contains bound signaling 
molecules that respond to incoming metabolic stress to regulate lipid and glucose 
metabolism. CREBH is a bZip transcription factor that is primarily expressed in the 
liver (10). It is localized in the ER of hepatocytes as an inactive, full-length, 
membrane-bound protein. In order to become an active transcription factor, CREBH 
must be cleaved, releasing the cytosolic portion of the protein (9). Activation can be 
Normal liver
Fatty liver 
(Steatosis)
Steatohepatitis
Increased FA delivery; 
hepatic lipogenesis; 
Insulin resistance
First hits
Oxidative stress;
Inflammatory cytokines;
Saturated FA; Endotoxin
Second hits
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caused by dietary, ER, or inflammatory stress conditions, such as proinflammatory 
cytokines TNFα, IL6, and IL1β, bacterial endotoxin lipopolysaccharide, insulin 
signaling, saturated FA, nutrient starvation, or AHF diet feeding (9, 12). CREBH 
migrates from the ER to Golgi apparatus where it is cleaved by Site-1 and Site-2 
proteases in a manner similar to that observed in the activation of SREBPs (9). 
Afterwards, the active, cytosolic region of CREBH may enter the nucleus to act as a 
transcription factor and induce expression of downstream target genes involved in 
lipid and glucose metabolism (Figure 4).  
 
 
Figure 4. Diagram of CREBH activation. Upon stress, CREBH migrates from the ER 
to the Golgi Apparatus to undergo cleavage. The cleaved portion of CREBH induces 
transcription of downstream targets. 
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CREBH regulates many lipid and glucose metabolic pathways (13). In fact, 
previous studies performed in our laboratory have shown that this multi-faceted 
behavior maintains homeostasis by inducing opposing metabolic processes, such as 
lipolysis and lipogenesis or FA elongation and oxidation (12). Upon longer-term 
feeding of AHF, more advanced manifestations of metabolic syndrome become 
apparent. Upon six-month feeding of AHF, CrebH-null mice develop symptoms of 
NASH not found in wild-type mice under the same feeding conditions (12). 
Hepatocytes from these diet-treated CrebH-null mice exhibit increased size and lipid 
droplet content. Livers from these mice demonstrate inflammation and morphological 
changes accompanying the increase in lipid content. Additionally, serum TG levels 
are increased in CrebH-null mice compared to wild-type mice after diet treatment. 
This elevated level of serum TG content is known as hypertriglyceridemia. CREBH 
was later shown to regulate to expression of ApoA4, a gene involved in lipolysis (69). 
The role of CrebH in metabolite regulation is not limited to mice. A 2012 study 
showed that rare variants in the human CREBH gene contribute to the development 
of hypertriglyceridemia in human patients (70). 
CREBH has been shown to play a vital role lipogenesis upon induction of ER 
stress. Primary hepatocytes from wild-type and CrebH-null mice were treated with the 
ER stress inducing substances, tunicamycin and palmitic acid (12). Wild-type primary 
hepatocytes exhibited the development of lipid droplets indicative of functional ER 
stress-induced lipogenesis. Primary hepatocytes from CrebH-null mice were unable 
to produce lipid droplets at levels comparable to cells from the wild-type mice. 
CREBH was also shown to transcriptionally regulate the Fsp27 gene, which is 
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important in lipid droplet formation (71). These results indicate a complex and, at 
times, paradoxical role for CREBH in lipid metabolism.  
CREBH has also been demonstrated as major player in gluconeogenesis in 
the liver. Lee et al. showed that CrebH mRNA, along with that of gluconeogenic 
enzymes, was upregulated during fasting (13). Additionally, CrebH overexpression 
upregulated the mRNA levels of Pepck and G6pc. In rat primary hepatocytes, CrebH 
overexpression increased glucose output. CrebH-knockdown reduced fasting blood 
glucose levels in both wild-type and hyperglycemic db/db mice. These results show 
that CREBH activation during fasting induces gluconeogenesis. 
1.6 FGF21 
FGF21 is a metabolic hormone that is expressed preferentially in the liver and 
regulates lipid and glucose metabolism at a systemic level (72). It is a member of the 
FGF family of proteins that is commonly associated with cell proliferation. FGF21 
differs from this convention by not playing a role in cell proliferation and instead 
regulating energy metabolism pathways. Activity of FGF21 is associated with 
antiobesity and antidiabetic effects (73, 74). These characteristics have caused 
FGF21 to be a focus of clinical trials. 
In mice, FGF21 is secreted by multiple organs, though primarily liver, in 
response to metabolic stress. These stresses include fasting, high-fat diet, and high-
sucrose diet. Under high-fat diet and fasting conditions, Fgf21 expression is up-
regulated by PPARα (75, 76). Upon secretion, the FGF21 protein enters circulation 
where it signals to target tissues, which include liver, adipose, pancreas and brain. 
Signaling is carried out by interaction with β-Klotho and FGF receptor (77). After 
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FGF21 has entered circulation, the protein half-life is approximately 30 minutes, but 
its metabolic effects last for 24 hours in peripheral tissues (78, 79). In human 
hypertriglyceridemia patients, fenofibrate treatment resulted in increased serum 
FGF21 levels (80). 
Under fasting conditions, FGF21 activity stimulates FA oxidation and 
ketogenesis (37). During the fed state, FGF21 produced in the adipose tissue 
regulates Pparγ expression. The metabolic consequences of FGF21 signaling vary 
from tissue to tissue. In liver, FGF21 signaling induces gluconeogenesis, FA 
oxidation, and ketogenesis. Adipose tissue undergoes decreased lipolysis and 
increased thermogenesis and glucose uptake in response to FGF21 signaling. 
FGF21 signaling in brain alters behavior, increasing food intake and energy 
expenditure. 
Due to its effects on multiple tissues and control over metabolic function, 
FGF21 has been the focus many studies aimed at rescuing disease phenotypes. In 
obese mice, prolonged administration of FGF21 protein resulted in pronounced 
weight loss (81). Furthermore, overexpression of Fgf21 in mouse liver protected 
these mice from diet-induced weight gain (79). In mice that have developed diet-
induced NAFLD, exogenous FGF21 protein administration was proven effective in 
reducing liver lipid content (82). In diabetic cynomolgus monkeys, FGF21 mimetic 
administration improved the overall serum lipid profile (83). These animals showed 
decreased serum TG, cholesterol and LDL content. This improvement coincided with 
decreased fasting serum glucose and insulin levels and an increase in serum HDL 
levels. Obese mice, while responsive to exogenous FGF21 administration, have 
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elevated FGF21 serum levels and are FGF21-resistant (84). Elevated serum levels of 
FGF21 in humans have been associated with hepatic steatosis, insulin resistance, 
hypertriglyceridemia, and type 2 diabetes (37). 
The promising results of rescue experiments in animal disease models, 
coupled with the mildness of side effects, FGF21 has been a focal point for 
therapeutic research. Research in this area has aimed toward improving stability of 
the protein in circulation, sensitizing tissues to FGF21 signaling, and increasing 
bioavailability of administered protein (79, 85, 86). Despite evidence of FGF21 
resistance in patients who are most likely to benefit from the treatment, therapeutic 
FGF21 administration remains a viable avenue of research, due to effectiveness of 
FGF21 treatment in FGF21 resistant animal models. Currently, an FGF21 analogue, 
called LY2405319, has shown promise in clinical testing (87, 88). 
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CHAPTER II: Defining the Phenotype of CrebH-null Mice Under 
Metabolic Stress 
 
2.1 Summary 
 In this chapter, we define the phenotype of CrebH-null mice under three 
sources metabolic stress: fasting, AHF diet, and high-sucrose diet. CrebH-null mice 
were shown to be susceptible to hyperlipidemia during fasting and AHF diet-feeding. 
These mice were also defective in ketogenesis. Quantitative real-time PCR analysis 
reveals CREBH-mediated regulation of genes involved in lipid clearance and 
ketogenesis. CrebH-null mice have been shown to be more susceptible to AHF diet-
induced non-alcoholic fatty liver disease than wild-type counterparts. Enzymatic and 
histological analysis of liver tissue from AHF diet-fed CrebH-null and wild-type mice 
indicated elevated levels of lipid content in CrebH-null mice. High-sucrose diet-
feeding is proposed as a novel inducer of CREBH activity. After 5 weeks of high-
sucrose feeding, evidence suggests that CrebH-null mice were protected from diet-
induced insulin resistance. Additionally, CREBH regulates expression of the 
metabolic hormone, Fgf21, under fasting, high-sucrose diet, and AHF diet stresses. 
CREBH-mediated regulation of Fgf21 was confirmed by gain-of-function analysis in 
mice expressing exogenous CREBH. 
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2.2 Materials and methods 
Materials 
Chemicals were purchased from Sigma unless indicated otherwise. Synthetic 
oligonucleotides were purchased from Integrated DNA Technologies, Inc. (Coralville, 
IA). Human insulin was purchased from Eli Lilly (Indianapolis, IN). Antibody against 
murine CREBH was made in our laboratory as previously described (9). Mouse 
monoclonal anti-FGF21 antibody and FGF21 ELISA kit were from R & D Systems, 
Inc. (Minneapolis, MN). Kits for measuring TG, FA, and the ketone body, 3-
hydroxybutyric acid were purchased from BioAssay Systems, Inc. (Hayward, CA).  
Mouse experiments 
The CrebH-null mice with deletion of exons 4–7 of the CrebH gene have been 
previously described (8). Wild-type control mice on a C57Bl/6J background of 
approximately 3-months of age were used for the metabolic diet study. Unless 
otherwise stated, all animals were fed ad libitum with Laboratory Rodent Diet 5001 
from Lab Diet. For the atherogenic high-fat (AHF) diet study, the AHF diet (16% fat, 
41% carbohydrate, 20% protein, 1.25% cholesterol , supplemented with 0.5% sodium 
cholate by weight) was purchased from Harlan Laboratories, Inc. (TD.88051). For the 
high-sucrose diet study, the high-sucrose diet (5.2% fat, 18.3% protein, and 61.7% 
carbohydrate by weight, with 53% of carbohydrate calories coming from sucrose) was 
provided by Harlan Laboratories Inc. (TD.88122). All the animal experiments were 
approved by the Wayne State University IACUC committee and carried out under the 
institutional guidelines for ethical animal use. For all fasting procedures, mice were 
housed in cages containing Pure-o’Cel bedding. Mice were provided water, but no 
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food for 6, 12, 14, or 24 hours. Tissue collection or glucose tolerance test were 
performed immediately after the fasting period. 
Food intake and fat mass measurements 
The CrebH-null and wild-type mice were subjected to food intake 
measurement under the normal chow diet. Food consumption was determined by 
measuring diet weights every 12 hours. Daily food intake was determined based on 
food consumption in 24 hours, measured daily for one week. The whole body fat 
mass of the CrebH-null and wild-type mice was determined by using the EchoMRI 
system for living animals according to manufacturer’s instruction (Echo Systems, 
Houston, TX).  
Measurement of mouse lipid contents 
Liver tissue and blood plasma samples were isolated from the mice under the 
normal chow diet, after fasting, or after the AHF diet. To determine hepatic TG levels, 
approximately 100 mg liver tissue was homogenized in PBS followed by 
centrifugation. The supernatant was mixed with 10% Triton-100 in PBS for TG 
measurement using a commercial kit (BioAssay Systems, Hayward, CA). Mouse 
blood plasma samples were subjected to quantitative analyses of plasma TG, total 
cholesterol, HDL, and LDL as previously described (12). Levels of the ketone body 
metabolite, 3-hydroxybutyric acid in the plasma were determined using commercial 
kits (BioAssay Systems).  
Oil-red O staining 
Frozen liver tissue sections were stained with Oil-red O for lipid contents 
according to standard protocol. Briefly, frozen liver tissue sections of 8 microns were 
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air-dried, and then fixed in formalin. The fixed sections were rinsed with 60% 
isopropanol before they were stained with freshly prepared Oil-red O solution for 15 
minutes. After Oil-red O staining, liver sections were rinsed again with 60% isopropanol 
followed by washing with water before subjected to microscope analysis.  
Quantitative real-time PCR 
For real-time PCR analysis, the reaction mixture containing cDNA template, 
primers, and SYBR Green PCR Master Mix (Applied Biosystems) was run in a 7500 
Fast Real-time PCR System (Applied Biosystems, Carlsbad, CA). Fold changes of 
mRNA levels were determined after normalization to internal control β-actin mRNA 
levels. The sequences of real-time PCR primers used in this study are shown in 
appendix A.  
Adenovirus injection 
Adenovirus-expressing GFP (Ade-GFP) or the activated CREBH (Ade-
CREBH) were injected to wild-type mice through tail-vein injection. Approximately 1 × 
1010 PFU of adenovirus in 0.3 ml PBS were injected into a mouse of approximately 
20 gram body weight. Three days after the injection, the liver tissues and blood 
samples were collected from the CrebH-null and wild-type control mice under feeding 
or fasting condition for further analyses. 
FGF21 Enzyme-linked Immunosorbent Assay (ELISA) 
Mouse blood serum were collected for FGF21 ELISA analysis. The analysis 
was performed using mouse monoclonal anti-FGF21 antibody and FGF21 ELISA kit 
from R & D Systems, Inc. (Minneapolis, MN) according to the manufacture’s 
instruction.  
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Glucose tolerance test (GTT) and insulin tolerance test (ITT) 
 Glucose tolerance was measured after intraperitoneal (i.p.) injection of 2mg 
glucose/gram body weight into overnight-fasted CrebH-null and wild-type control 
animals. For the insulin tolerance test, mice were fasted for 4 hours before i.p. 
injection of human insulin (0.75 mU/g body weight). Blood glucose levels were 
measured from tail blood using an OneTouch Ultra glucometer (Johnson & Johnson). 
Statistics 
Experimental results are shown as mean ± SEM (for variation between 
animals or experiments). The mean values for biochemical data from the 
experimental groups were compared by a paired or unpaired, 2-tailed Student’s t test. 
Statistical tests with P < 0.05 were considered significant. 
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2.3 Results 
Previous studies have shown that CREBH cleavage and activation can be 
effected by ER stress, inflammatory stimuli, and metabolic stress (8, 9, 12). In 
addition to mediating hepatic acute-phase response, CREBH has been shown to 
have a drastic effect on the ability of mice to cope with metabolic stress caused by 
high-fat diet feeding. To further explore the role of CREBH on physiological 
adaptation to metabolic stress, CrebH-null and wild-type control mice were exposed 
to fasting conditions or fed with the AHF or high-sucrose diet.  
 
 
Fasting has been previously shown to induce CREBH activity (13, 89). Serum 
TG were elevated in CrebH-null mice compared to those of the wild-type control 
under feeding conditions, but serum FA and BOH levels remained similar between 
the groups (Figure 5). However, after overnight fasting, more discrepancies between 
Figure 5. Metabolite levels in serum 
from wild-type and CrebH-null mice 
under metabolic stress. Levels of (A) 
triglyceride, (B) fatty acid, and (C) BOH 
were analyzed under feeding, fasting, 
and AHF diet conditions. Each bar 
denotes the mean SEM (n = 8 WT or 
KO mice under feeding or fasting 
condition; n = 6 WT or KO mice under 
the AHF diet). *, P ≤ .05; **, P ≤ .01 
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the CrebH-null and wild-type mice serum metabolites begin to manifest. These 
include increased levels of serum TG and FA that coincide with decreased levels of 
BOH in the CrebH-null mice. After feeding wild-type and CrebH-null mice with an 
atherogenic high fat diet for 6 months, CrebH-null mice possess higher levels of 
hepatic TG compared to wild-type mice, as indicated by both Oil-red staining of liver 
tissue sections and quantitative enzymatic analysis of hepatic TG levels (Figure 6). 
Additionally, serum TG and FA levels were significantly increased in CrebH-null mice, 
while serum BOH levels were lowered in these mice (Figure 5). Furthermore, CrebH-
null mice exhibited decreased body fat mass compared to wild-type mice under a 
normal chow diet (Figure 7B). This reduction in fat mass coincided with a slightly 
decreased weight compared to wild-type mice (Figure 7A). Food consumption was 
measured under these conditions, and CrebH-null and wild-type mice were found to 
consume similar amounts of food (Figure 7C). This finding excludes food intake as a 
factor in the differences in body and fat mass observed in our testing groups. 
Figure 6. Hepatic lipid content analysis after AHF diet. (A) Oil Red O staining of liver 
tissue sections from mice after 6 months of AHF diet feeding. CrebH KO mice exhibit 
drastically increased lipid droplet content as well as hepatocyte size compared to 
wild-type mice. (B) Quantitative, colorimetric assay of hepatic triglyceride content. ** p 
≤ 0.01. 
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Figure 7. Physiological comparison of wild-type and CrebH-null mice after AHF diet-
feeding. (A) Body weight comparison (B) Body fat mass determined by MRI. (C) Food 
consumption. * p ≤ 0.05. 
 
Previously, we performed gene microarray analysis with CrebH-null and wild- 
type control mice fed either normal chow or AHF diet (12). The microarray analysis 
implicated that most CREBH-regulated genes are involved in lipid metabolism, 
specifically TG metabolism, cholesterol and sterol biosynthesis, FA oxidation, and 
ketogenesis. In order to identify genes that undergo CREBH-mediated, fasting-
induced upregulation, wild-type and CrebH-null mice were exposed to feeding or 16-
hour fasting conditions. Liver tissues were collected from these mice and quantitative 
real-time PCR was performed to identify CREBH-regulated genes (Figure 8). My 
analysis identified that the genes Fgf21, apolipoprotein (Apo) C-II (ApoC2), ApoA5, 
and lactate dehydrogenase A (Ldha) are regulated by CREBH in mouse liver under 
fasting conditions. Expression levels of these genes did not differ in wild-type and 
CrebH-null mice under feeding conditions. Upon fasting, wild-type mice showed a 
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modest but significantly higher level of expression for these targets than CrebH-null 
mice. 
Just as the targets of CREBH regulation varied under differing metabolic 
stresses, the fasting-induced effect of CREBH on target gene expression may vary 
under differing fasting conditions. In our experiment, groups of three male wild-type 
mice were paired with groups of three male CrebH-null mice and fasted for 6, 12 or 
24 hours beginning at 6 pm. Immediately after fasting, mice were sacrificed and liver 
tissue samples were collected. Fed wild-type and CrebH-null mice liver tissue 
samples were collected as controls. Quantitative, real-time PCR was performed to 
determine hepatic gene expression. In this experimental setting, I identified that 
CREBH regulates hepatic expression of the Fgf21, Bdh1, and Ldha genes in mice 
upon different periods of fasting (Figure 9). Fed wild-type and CrebH-null mice 
showed relatively low baseline expression levels of Fgf21 mRNA. Fgf21 upregulation 
was strongest in the 6- and 12-hour fasted wild-type mice, but showed a more 
modest increase in the 24-hour fasted wild-type group. In contrast, CrebH-null mice 
displayed a similar pattern in Fgf21 expression pattern, but mRNA levels were 
roughly 10-fold lower than in their wild-type counterparts (Figure 9).  
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Figure 8. Quantitative real-time PCR analysis of fasting-induced gene transcriptional 
regulation in CrebH-null (KO) and wild-type (WT) control mice under fasting and fed 
conditions. Fold changes of mRNA expression levels were calculated after 
normalization to that of β-actin. Bars denote mean values ± SEM (n=3). * p≤ 0.05. 
 
Expression levels of the Bdh1 and Ldha mRNAs were similar in both wild-type 
and CrebH-null mice under feeding conditions. However, under 12-hour fasting, 
expression levels of the Bdh1 and Ldha mRNA in CrebH-null mice were significantly 
lower than those in the control mice (Figure 9). This difference persisted in Bdh1 
expression levels after 24-hour fasting, as well. 
* 
* 
* 
* * 
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Figure 9. Quantitative real-time PCR analysis of variable-length fasting-induced gene 
expression in CrebH-null (KO) and wild-type (WT) control mice. Liver tissue mRNA 
samples from wild-type and CrebH-null mice under fed and 6-, 12-, and 24-hour 
fasting conditions were compared. Fold changes of mRNA expression levels were 
calculated after normalization to that of β-actin. Bars denote mean values ± SEM 
(n=3). * p≤ 0.05. ** p≤0.01.  
 
In addition to fasting, I tested the regulation of FGF21 expression by CREBH 
under metabolic stress-inducing diets. Previous studies have shown that Fgf21 
expression is augmented by diets that are high in sucrose (90). To test whether 
CREBH plays a role in this upregulation, wild-type and CrebH-null mice were fed a 
normal or high-sucrose diet for 5 weeks. After the feeding period, mice were 
euthanized and mouse livers were collected. Quantitative real-time PCR analysis 
revealed that Fgf21 expression shows a marked increase in wild-type mice under the 
high-sucrose feeding regimen that is absent in CrebH-null mice under the same 
treatment (Figure 10). Moreover, CrebH-null and wild-type control mice were fed with 
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the AHF diet for 6 months. The AHF diet (also called the Paigen diet) is known to 
induce atherosclerosis and NAFLD in rodent models (91, 92). Similar to the fasting 
and high-sucrose-diet-fed conditions, the liver of the CrebH-null mice expressed 
significantly lower levels of the Fgf21 mRNA, compared to that of the wild-type control 
mice, after AHF diet-feeding. 
 
 
Figure 10. Quantitative real-time PCR results for high-sucrose and normal diet-fed 
mice. Wild-type mice showed a statistically significant increase in Fgf21 expression 
under high-sucrose diet that is not present in CrebH-null mice. High-sucrose diet-
treated wild-type mice showed no increase in CrebH expression. Fold changes of 
mRNA expression levels were calculated after normalization to that of β-actin. Bars 
denote mean values ± SEM (n=3). * p≤ 0.05. 
 
High-fat diets have been shown to cause NAFLD and high sucrose diets are 
known to induce insulin resistance (92, 93). In order to outline the physiological 
effects of CREBH under dietary stress, I performed a glucose tolerance test (GTT) 
and insulin tolerance test (ITT) on wild-type and CrebH-null mice under normal, high-
sucrose, and AHF diet-feeding conditions. Under the normal chow diet, CrebH-null 
* 
29 
   
 
and wild-type mice displayed similar patterns of blood glucose clearance in response 
to exogenous glucose or insulin challenge (Figures 11 A and B). After feeding the 
mice with AHF diet for six months, CrebH-null and wild-type mice still had similar 
response patterns to infusion of exogenous glucose (Figure 11C). However, the 
CrebH-null mice showed no response to insulin challenge during ITT (Figure 11D). It 
is notable that CrebH-null mice displayed lower levels of blood glucose compared to 
the wild-type control mice, which can be explained by the role of CREBH in 
gluconeogenesis (Figure 11) (13). Surprisingly, when GTT was performed on mice 
that were fed the high-sucrose diet, the CrebH-null mice were better able to clear 
infused glucose than were wild-type mice (Figure 12A). This effect was quantified 
using the incremental area under the curve method and found to be statistically 
significant. To determine if this was due to insulin resistance that was present in wild-
type mice and absent in CrebH-null mice, these mice were sacrificed and livers were 
collected. Because AKT phosphorylation is a downstream effect of insulin signaling in 
liver, the phosphorylation state of AKT was assessed by Western blot analysis 
(Figure 12C). Corroborating the results of the GTT, high-sucrose fed CrebH-null mice 
possessed higher levels of phosphorylated AKT, despite having somewhat lower 
levels of total AKT. 
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Figure 11. GTT and ITT analyses with CrebH-null and wild-type control mice after 
normal or AHF diet. Fasted mice were infused with glucose or insulin via I.P. 
injection. Blood glucose was measured before injection and at intervals during the 2-
hour recovery period. (A,B) GTT and ITT of mice after normal chow diet feeding. 
(C,D) GTT and ITT of mice after AHF diet feeding. Bars denote mean values ± SEM 
(n=3). 
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Figure 12. Glucose tolerance test and 
AKT phosphorylation in high-sucrose 
diet-fed mice. (A-B) After high-sucrose 
feeding, CrebH KO mice showed 
increased ability in clearing blood 
glucose in response to exogenous 
glucose challenge compared to WT 
mice. (C) KO mice showed higher 
levels of AKT phosphorylation than 
WT mice after high-sucrose feeding. 
Bars denote mean values ± SEM 
(n=8). * p≤ 0.05. 
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Taken together, my studies suggested that CREBH regulates expression of 
FGF21, a hepatic hormone that regulates whole-body energy metabolism, under the 
metabolic stress conditions induced by fasting, the AHF diet, or the high-sucrose diet. 
To confirm this regulation at the protein level, I examined serum levels of FGF21 in 
the CrebH-null and wild-type control mice upon fasting or in the mice over-expressing 
the activated form of CREBH or GFP control in livers. Upon 14 hours of fasting, 
serum levels of FGF21 in the CrebH-null mice were significantly reduced, compared 
to those of the control mice, as indicated by ELISA analysis (Figure 13A). 
Furthermore, an activated form of CREBH or GFP control was over-expressed in 
livers of wild-type control mice by using an adenoviral-based over-expression system. 
Over-expression of the activated CREBH in mouse liver dramatically increased 
serum levels of FGF21 in the mice after the fasting (Figure 13B), thus confirming the 
role of CREBH in regulating FGF21 production from the liver. 
 
Figure 13. CREBH activity increases FGF21 serum concentration. (A) CrebH KO 
mice show decreased Fgf21 expression upon fasting. (B) Overexpression of CrebH 
upregulates Fgf21 expression. Serum levels of FGF21 were determined by ELISA. 
The bars denote mean values ± SEM (n=3). * p≤ 0.05; ** p≤ 0.01. 
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2.4 Discussion 
It has been documented that both CrebH and Fgf21 are upregulated by fasting 
(76, 89). Although CREBH is known to play important roles in transcriptional 
regulation of hepatic lipid metabolism, the regulatory targets of CREBH under 
metabolic stress have only begun to be investigated. After identifying the key role that 
CREBH plays in lipid and ketone regulation under AHF diet-induced metabolic stress, 
a logical next step would be to characterize the role of CREBH in managing these 
metabolites under fasting-induced metabolic stress. Our quantitative real-time PCR 
analysis revealed fasting-induced targets of CREBH (Figure 8). One of these targets, 
HMG-CoA synthase, is an enzyme responsible for production of HMG-CoA, an 
upstream metabolite of both ketone body and cholesterol synthesis (94). This 
corroborates the notable decrease in serum ketone body concentration (Figure 5). 
Additionally, this provides an explanation for the previous finding that CrebH-null mice 
present lower levels of cholesterol (total cholesterol, HDL, and LDL) (12). 
The Ldha gene codes the M subunit of the LDH complex (95, 96). This subunit 
entirely composes the LDH-5 complex, the isozyme present in liver tissue (95). This 
enzyme converts lactic acid to pyruvate in the liver as part of the Cori cycle (97). The 
resulting pyruvate then feeds in to gluconeogenesis pathway. The lower level of Ldha 
in liver tissues of CrebH-null mice under fasting conditions could be a contributing 
factor to the low blood glucose level seen in these animal models (Figure 8) (12, 13). 
The Ldha fasting expression pattern shows a steady increase as fasting length 
increases in wild-type mice (Figure 11). This increase is not present in the CrebH-null 
mice, which maintains a similar expression level at all time points. This pattern 
34 
   
 
indicates a third regulation pattern that consistently increases over the course of the 
fast and is entirely dependent on CREBH activity. The fact that the CrebH-null mice 
maintain a steady level of Ldha expression that is similar to that of wild-type mice 
under the feeding condition shows that CREBH is not necessary to maintain the base 
line level of Ldha expression. 
Bdh1 is an enzyme involved in ketogenesis that was previously shown to be 
regulated by CREBH (11, 98). The fasting-induced expression profile of Bdh1 shows 
that wild-type mice have peak expression during the 12- and 24-hour fasting periods 
(Figure 11). These longer fasting periods represent time points when ketogenesis 
would become active. The CrebH-null mice do not show increased expression during 
these periods. This shows the necessity of CREBH in Bdh1 induction upon fasting 
and indicates the importance of CREBH in ketogenesis. 
Apolipoproteins are proteins involved in lipid transport and lipolysis (99). Two 
apolipoproteins, ApoA5 and ApoC2, were down-regulated in fasting CrebH-null mice 
compared to fasting wild-type mice (Figure 10). These two genes have previously 
been shown to be regulated by CREBH under a high-fat diet (12). ApoA5 is involved 
in the formation of lipid-carrying lipoprotein particles, such as HDL and VLDL (100). 
ApoC2 facilitates the interaction between lipoprotein particles and lipoprotein lipase 
(101). This interaction is important for delivery of the TG to peripheral tissues. 
Because apolipoproteins are core components of lipid-carrying particles, they are 
essential to lipid clearance in blood, and human polymorphisms in these genes are 
linked to hyperlipidemia (102). Our previous studies have shown that CrebH-null mice 
demonstrate hyperlipidemia when fed an AHF diet (12). I have demonstrated that 
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hyperlipidemia occurs in CrebH-null mice under fasting conditions, as well (Figure 5). 
The hyperlipidemia phenotype is likely due to down-regulation of ApoC2 and ApoA5 
in CrebH-null mice. Additionally, owing to the importance of these proteins in delivery 
of lipids to peripheral tissues, the absence of ApoC2 and ApoA5 in CrebH-null mice 
may be responsible for the small fat pads present in these mice under the AHF diet 
compared to wild-type mice under the same diet (12).  
A critical gene regulated by CREBH under fasting is Fgf21 (Figure 8). 
Previously, through microarray gene expression analysis, we identified several 
groups of CREBH-regulated genes that are involved in lipolysis, FA oxidation, and 
lipogenesis (12). However, how CREBH modulates perplex genetic programs 
involved in multiple lipid metabolic pathways remains to be elucidated. FGF21 is a 
fasting-induced hormone responsible for activating multiple metabolic stress 
response pathways (76). FGF21 exerts pleiotropic effects on hepatic FA oxidation, 
ketogenesis, and lipolysis by reprogramming gene transcription in lipid metabolism in 
the liver upon fasting or under a methionine- and choline-deficient (MCD) diet (76, 
103, 104). Identifying Fgf21 as a target of CREBH may explain the role of CREBH in 
lipid metabolism during states of metabolic stress. Fgf21 displays an interesting 
expression pattern upon fasting (Figure 9). In wild-type mice, Fgf21 expression peaks 
during the 6- and 12-hour fast, but begins to lower during the 24-hour fast. This 
pattern is the same in CrebH-null mice, but the relative mRNA levels are 
approximately 10-fold lower. In this case, another factor seems to be regulating the 
pattern of expression based on the length of the fast, but CREBH appears to be 
upregulated FGF21 during all of the fasting periods studied. Fgf21 has also been 
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shown to be up-regulated by dietary sucrose ingestion (90). Our own high-sucrose 
diet experiments corroborate this observation (Figure 10). However, Fgf21 mRNA 
levels are not increased in CrebH-null mice under high-sucrose diet. This implies that 
sucrose-dependent Fgf21 mRNA level increases are mediated by CREBH. 
Interestingly, mRNA levels of CrebH are not affected by the high-sucrose diet. This is 
similar to the CrebH mRNA level observed in mice under the AHF diet, which also 
showed an increase in Fgf21 mRNA levels. A distinction between the high-sucrose 
and the AHF diets, though, is the lack of increased expression of Pparα mRNA in 
high-sucrose diet-fed mice (105). The link established between FGF21 and CREBH 
in these experiments led us to investigate the relationship between these two proteins 
and possible role of FGF21 as a mediator of CREBH.  
Previous studies have shown that CrebH mediates different metabolic 
processes depending on the type of stress endured by the hepatocyte (9, 12, 13, 89). 
Some of the processes that CrebH regulates are even in opposition to each other 
(e.g. lipolysis under AHF-feeding and lipogenesis under ER stress). We hypothesized 
that CREBH may initiate different fasting-induced pathways based on the length of 
the fasting stress. We designed an experiment to test the effect of various fasting 
conditions on CREBH target gene expression. If CREBH does differ in its regulatory 
targets based on different fasting conditions, we should expect to see CREBH targets 
displaying different expression profiles for individual genes. Indeed, multiple profiles 
were identified, confirming this hypothesis (Figure 9). However, CrebH itself shows 
only a modest increase in expression due to fasting. This may be misleading, though, 
as CREBH activity cannot be accurately expressed by its mRNA level. CREBH 
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activity is also regulated at the protein level by RIP-mediated cleavage (Figure 4). 
Additionally, as we will demonstrate in the following chapter, a binding partner can 
modify the transcriptional activity of CREBH.  
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CHAPTER III: CREBH Works in Concert with PPARα to Regulate 
Fgf21 Expression  
 
3.1 Summary 
 In the previous chapter, the regulatory relationship between CREBH and Fgf21 
was established. In this chapter, we define the mechanism by which CREBH 
regulates Fgf21 expression. Analysis of the Fgf21 gene promoter identified highly-
conserved CRE and PPRE1/2 response elements in close juxtaposition, indicating 
protein-DNA binding sites for CREBH and PPARα. DNA binding of CREBH and 
PPARα was confirmed by ChIP analysis. Site-mutation was performed to generate 
mutant FGF21 promoter regions, representing mutations in each of newly discovered 
response elements, for luciferase reporter assay. Reporter assay indicated that the 
CRE and PPRE2 are vital to CREBH- and PPARα-mediated Fgf21 expression. 
CREBH and PPARα act in synergy to induce expression of the Fgf21 gene promoter. 
Moreover, the proximity of the binding sites suggested a possible protein-protein 
interaction between CREBH and PPARα. This discovery of the possible interaction 
was followed by verification of the interaction and investigation of its importance. IP-
Western blotting analysis showed that CREBH and PPARα interact under fasting- 
and AHF diet-induced stress. CREBH and PPARα were shown to be necessary for 
proper expression of Fgf21 during fasting-induced metabolic stress. Our study found 
that CREBH and PPARα regulate each other transcriptionally and interact with each 
other to induce Fgf21 transcription. 
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3.2 Materials and Methods 
Materials  
Chemicals were purchased from Sigma unless indicated otherwise. Synthetic 
oligonucleotides were purchased from Integrated DNA Technologies, Inc. (Coralville, 
IA). Antibodies against flag and β-actin were purchased from Sigma. Mouse 
monoclonal anti-PPARα antibody was purchased from Millipore (Billerica, MA), 
Mouse monoclonal anti-FGF21 antibody and FGF21 ELISA kit were purchased from 
R & D Systems, Inc. (Minneapolis, MN). Polyclonal anti-CREBH antibody used for 
Western blot analysis was raised in our laboratory as previously described (106). Kits 
for measuring TG and FA were from BioAssay Systems (Hayward, CA).  
Mouse experiments 
The CrebH-null mice were previously generated as described (8). The Pparα-
null mice were purchased from the Jackson Laboratories. The CrebH-null, Pparα-null, 
and wild-type control mice on a C57Bl/6J background at approximately 3-month-old 
were used for the experiments. All the animal experiments were approved by the 
Wayne State University IACUC committee and carried out under the institutional 
guidelines for ethical animal use. 
Cell culture experiments 
The hepatocarcinoma cell line Huh-7 was kindly provided by Dr. Charles Rice 
at the Rockefeller University [1]. Huh-7 cells were plated on 10-cm plates and 
maintained in DMEM/High Glucose media containing 100 units/ml penicillin, 100 
μg/ml streptomycin, and 10% fetal bovine serum. The cells at about 60% confluence 
were infected with adenovirus-expressing GFP (Ade-GFP), adenovirus-expressing 
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CREBH (Ade-CREBH), adenovirus-expressing PPARα (Ade-PPARα), or combination 
of Ade-CREBH plus Ade-PPARα at an MOI of 100 for 48 hours before they were 
collected for ChIP analyses. 
ChIP assay 
The Huh-7 cells were infected with equal amounts of Ade-GFP, Ade-CREBH, 
Ade-PPARα, or combination of Ade-CREBH and Ade-PPARα. To determine the 
binding of CREBH and/or PPARα to the FGF21 promoter region, we used a 
commercial ChIP assay kit (Millipore, MA) according to the manufacturer’s instruction 
with modifications as previously reported (106). A polyclonal anti-CREBH antibody or 
a monoclonal anti-PPARα antibody (Millipore, MA) was used for IP. The genomic 
DNA controls isolated from sonicated cell lysates and immunoprecipitated DNAs 
were both extracted with the chelex-100 kit (Bio-Rad, CA). For the cross-link 
procedure, formaldehyde was added directly to the medium to a final concentration of 
1%. The cultures were incubated for 10 min at 37 ˚C. Cells were washed with ice-cold 
PBS containing protease inhibitors and collected by centrifugation. Cell pellets were 
re-suspended in 200 μl SDS lysis buffer, and were sonicated to obtain DNA 
fragments of 200-1000 bp. For the PCR analysis, 1 μl DNA sample was mixed with 5 
μM human FGF21 forward primer (5’-ATTCAGGCTGCCCTTGCCACG-3’), 5 μM 
human FGF21 reverse primer (5’-GCCTGGCTCCTCTTTCGGC-3’), and 18 μl PCR 
supermix. As a control, PCR reaction was 3 carried out with the control primers 
(forward; 5’ CACCAGGGTCTCCGATCTCCCA-3 and reverse; 5’-
TGCTGGAGGTGGGCCTTGGAC-3’). 
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Quantitative Real-time RT-PCR 
For real-time PCR analysis, the reaction mixture containing cDNA template, 
primers, and SYBR Green PCR Master Mix (Applied Biosystems) was run in a 7500 
Fast Real-time PCR System (Applied Biosystems, Carlsbad, CA). Fold changes of 
mRNA levels were determined after normalization to internal control β-actin mRNA 
levels. The primer sequences are described in Appendix A. 
Western Blot analysis 
Total cell lysates were prepared from either liver tissue or cultured cells using 
NP-40 lysis buffer (1% NP-40, 50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 0.05% SDS, 
0.5 mM Na vanadate, 100 mM NaF, 50 mM β-glycerophosphate, and 1 mM 
phenylmethylsulfonyl fluoride) supplemented with protease inhibitors (EDTA-free 
Complete Mini, Roche) as previously described (107). Denatured proteins were 
separated by SDS-PAGE on 10% Tris-glycine polyacrylamide gels and transferred to 
a 0.45-mm PVDF membrane (GE Healthcare) followed by Western blot analysis with 
anti-CREBH, anti-PPARα, anti-FGF21, or anti-β actin antibody. Membrane-bound 
antibodies were detected by chemiluminescence detection reagents (GE Healthcare). 
Immunoprecipitation (IP) – Western blot analysis 
The interaction between CREBH and PPARα was determined by IP-Western 
blot assay. For preparation of the whole lysates, liver tissues were homogenized and 
lysed with Nonidet P-40 lysis buffer containing protease inhibitor cocktail as 
previously described (107). For IP, 200 μg of the whole lysate were incubated with 3 
μg of specific protein antibody for overnight at 4°C. Immunoprecipitated proteins were 
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resolved by SDS-PAGE followed by immunoblotting using an anti-CREBH or anti-
PPARα antibody. 
Site-directed mutagenesis 
Site mutation was introduced into the CREB-PPRE binding motif in the FGF21 
gene promoter using the QuickChange II Site-directed Mutagenesis Kit (Stratagene) 
according to manufacturer’s instruction. All the constructed plasmid vectors were 
confirmed by DNA sequencing. All the reporter assays were performed in triplicate. 
The primers used for site-directed mutagenesis are: 5’-
CAAATATCACGCCACAGGAGTGGG-3’; and 5’-
CCCACTCCTGTGGCGTGATATTTG-3’. 
Luciferase reporter analysis 
For luciferase reporter analysis, we used Dual-Luciferase Reporter Assay 
System (Promega). Hepa1-6 cells were co-transfected with the reporter vectors and 
control reporter vector pGL4.7 and infected with adenovirus Ade-GFP, Ade-CREBH, 
Ade-PPARα, or Ade-CREBH plus Ade-PPARα. Luciferase assay was performed at 
48 hours after transfection/infection. Data graphs were presented after normalization 
of Firefly luciferase reporter activities to the control Renilla luciferase activities. 
Statistics  
Experimental results are shown as mean ± SEM (for variation between 
animals or experiments). All in vitro experiments were repeated with biological 
triplicates at least three times independently. Mean values for biochemical data from 
the experimental groups were compared by paired or unpaired, 2-tailed Student’s t 
tests. Multiple comparisons were compared with ANOVA and proceeded by ad hoc 
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statistical test when necessary. Statistical tests with P < 0.05 were considered 
significant. 
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3.3 Results 
After establishing the regulatory effect of CREBH on Fgf21 expression, our 
next step was to delineate the mechanism of this effect. Analysis of the Fgf21 gene 
revealed a highly-conserved cAMP response element (CRE) within the promoter 
region, 63 nucleotides upstream from the transcription start site (Figure 14). This site 
serves as a binding region for CREB protein family members, including CREBH, to 
initiate transcription (10, 108). Upstream from this element, in close proximity, is an 
also highly conserved PPAR response element (PPRE), which serves a binding 
region for PPAR proteins (109). The PPRE is composed of two individual binding 
elements, PPRE1 and PPRE2. The proximity of the binding sites suggests a possible 
interaction between CREBH and a PPAR protein.  
 
Figure 14. Inspection of conserved Fgf21 gene promoter region elements across 
mammalian species. cAMP response element (CRE) and PPAR response elements 1 
and 2 (PPRE-1 and PPRE-2) are highly conserved and in close proximity within the 
Fgf21 promoter region. 
 
In order to determine the contribution of the CRE, PPRE1, and PPRE2 binding 
elements in CREBH- and/or PPARα-mediated Fgf21 expression, we performed site 
directed mutagenesis for each of these regions (Figure 15). This process was used to 
produce four mutant forms of the Fgf21 promoter region. The FM13 mutant contained 
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an AC to TG conversion in the CRE element. The PE-M1 mutant contained an AT to 
CG conversion in the PPRE1 element. The PE-M2 mutant contained an AC to CG 
conversion in the PPRE2 element. The fourth mutant promoter region, PE-M12, 
contained both mutations present in the PE-M1 and PE-M2 mutants. The mutant 
promoter regions were fused to luciferase reporter genes (Figure 15A). The resulting 
plasmids were used to transfect Hepa1-6 cells. Reporter assays were performed after 
infection of the Hepa1-6 cells with adenovirus expressing GFP, CREB, CREBH, or 
PPARα (Figures 16 and 17). CrebH and PPARα overexpression were verified by 
Western blot analyses (Figure 18). CrebH overexpression was also verified by 
measurement of serum and hepatic TG (Figure 19). Exogenous expression of CREB 
showed no increase in reporter activity from the wild-type, PE-M1 or PE-M2 
promoters (Figure 16B). The wild-type, PE-M1, and PE-M2 promoters showed 
reporter activity under exogenous CrebH expression, however. Reporter activity from 
the PE-M2 promoter was slightly lower than from the wild-type and PE-M1 promoters 
under this condition. Exogenous expression of CrebH showed no reporter activity 
with the FM13 promoter (Figure 17A). The wild-type, PE-M1, and PE-M2 promoters 
showed reporter activity under co-overexpression of CrebH and GFP (Figure 17C). 
Reporter activities from the PE-M2 and PE-M12 promoters were slightly lower than 
from the wild-type and PE-M1 promoters under this condition, as well. Co-
overexpression of CrebH and GFP showed no reporter activity with the FM13 
promoter (Figure 17B). Co-overexpression of PPARα and GFP induced reporter 
activity of the PE-M1, PE-M2, PE-M12, and wild-type promoters; PE-M2 and PE-M12 
showed lower activity than PE-M1 and wild-type (Figure 17C). This condition showed 
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no reporter activity from the FM13 promoter (Figure 17B). Co-overexpression of 
CrebH and PPARα-induced the highest reporter activity in the wild-type, PE-M1, PE-
M2, and PE-M12 promoters (Figure 17C), suggesting a synergy of CREBH and 
PPARα in driving Fgf21 expression. This condition did not induce reporter activity 
with the FM13 promoter (Figure 17B).  
 
 
Figure 15. Site-directed mutagenesis of the human FGF21 gene promoter. WT, CRE-
mutated (FM13), PPRE1-mutated (PE-M1), and PPRE2-mutated (PE-M2) forms of 
the FGF21 promoter region. A fourth mutant that contained the mutations present in 
PE-M1 and PE-M2, called PE-M12, was also created. 
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Figure 16. Description of luciferase reporter assay. (A) Illustration of luciferase fused 
to WT and mutant promoter regions. (B) Reporter assay demonstrating the specificity 
of CREB binding in the Fgf21 promoter region. Hepa 1-6 cells were transduced with 
the WT or mutant form of the Fgf21 promoter fused to the luciferase promoter gene. 
Cells were transfected with a control plasmid, plasmid expressing CREB, or plasmid 
expressing CREBH. The bars denote mean values ± SEM (n=3 biological repeats). ** 
p≤ 0.01. 
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Figure 17. Reporter assay for the mutated Fgf21 promoter region. (A-C) Hepa 1-6 
cells were transiently transduced with expression vectors containing the WT or 
mutated Fgf21 promoter region linked to a luciferase reporter. (A) Cells expressing 
WT or FM1 linked reporter gene were infected with adenovirus expressing active 
CrebH. (B) Cells with WT or FM1 linked reporter gene were infected with adenovirus 
expressing active combinations of CrebH, Pparα, and GFP. (C) Cells with WT, PE-
M1, PE-M2, or PE-M12 linked reporter gene were infected with adenovirus 
expressing active CrebH, Pparα, and GFP. The bars denote mean values ± SEM 
(n=3 biological repeats). * p≤ 0.05; ** p≤ 0.01. 
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Figure 18. Western blot analysis to validate adenoviral overexpression of CrebH and 
PPARα in CrebH- or Pparα-null mice. (A) Hepatic CREBH content in Pparα-null mice 
overexpressing CrebH or GFP. (B) Hepatic PPARα content in CrebH-null mice 
overexpressing PPARα or GFP. 
 
  
Figure 19. Verification of CrebH-
expressing adenovirus using 
measurements of (A) serum TG, 
(B) hepatic TG, and (C) body 
weight in male wild-type mice 
after four months of AHF feeding. 
The bars denote mean values ± 
SEM (n=3 for GFP expressing 
mice and 4 for CREBH-
expressing mice). ** p≤ 0.01. 
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Real-time PCR analysis of CrebH-null and wild-type mice after a 14-hour 
overnight fast was performed and this analysis revealed targets of CREBH 
transcriptional regulation. Both CrebH and Fgf21 mRNA levels were upregulated in 
response to fasting in wild-type mice. This pattern is not observed in CrebH-null mice. 
Similar pattern is observed in PPARα mRNA levels (Figure 20). Real-time PCR for 
these genes was performed on Pparα-null mice and wild-type counterparts under 
fasting conditions. The expression profile of CrebH in Pparα-null mice resembled that 
of Pparα in CrebH-null mice. The mRNA levels of these genes are reflected in the 
levels of associated proteins in the null mouse models (Figure 21). Together, these 
data suggest a reciprocal regulation between CREBH and PPARα (i.e. CREBH and 
PPARα regulate each other for their induction upon fasting). 
 
Figure 20. Quantitative real-time PCR analysis of CrebH-null, Pparα-null, and wild-
type control mice under fed and fasting conditions. (A) CrebH, Fgf21, and Pparα 
mRNA levels in CrebH-null and wild-type mice. (B) CrebH, Fgf21, and Pparα mRNA 
levels in Pparα-null and wild-type mice. Fold changes of mRNA expression levels 
were calculated after normalization to that of β-actin. Bars denote mean values ± 
SEM (n=3). * p≤ 0.05; ** p≤0.01. 
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Figure 21. Western blot analysis of null mice under fed and fasting conditions. (A) 
CrebH, Fgf21, and Pparα protein levels in CrebH-null mice. (B) CrebH, Fgf21, and 
Pparα protein levels in Pparα-null mice. Results compared to β-actin expression. 
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In order to determine the individual contribution of PPARα and CREBH to the 
hepatic expression of Fgf21, an adenoviral rescue experiment was performed. Pparα-
null and CrebH-null mice were fasted and injected with CrebH- or Pparα-expressing 
adenovirus, respectively. These rescue-treated mice were compared to wild-type and 
untreated null mice under fed and fasting conditions. Liver and blood serum were 
collected. Real-time PCR was performed on liver tissue (Figure 22). Wild-type, fed 
mice showed a low, baseline level of Fgf21 mRNA expression, which was several-
fold lower than the expression level of wild-type mice under the fasting condition. This 
baseline level was matched in Pparα-null and CrebH-null mice under both fasting and 
feeding conditions. Fasted CrebH-null and Pparα-null mice that were injected with 
GFP-expressing adenovirus displayed baseline or lower than baseline levels of Fgf21 
expression. Pparα-null mice that overexpressed CrebH showed a significant increase 
in Fgf21 expression levels, compared to the fed, Pparα-null mice. However, these 
mice showed lower levels of Fgf21 expression than the wild-type, fasted mice. 
CrebH-null mice that overexpressed Pparα displayed only a baseline expression level 
of Fgf21 mRNA. Western blot analysis showed that serum FGF21 protein levels 
varied slightly from hepatic Fgf21 mRNA levels (Figure 23). Serum FGF21 protein 
levels were low or undetectable in wild-type mice under the fed condition. Fasted, 
wild-type mice had observably higher FGF21 serum levels than fed, wild-type mice. 
Serum FGF21 levels of CrebH-overexpressing, fasted Pparα-null mice were similar to 
those from the fasted wild-type mice. Serum FGF21 levels of fasted CrebH-null mice 
over-expressing Pparα were detectable, but notably lower than wild-type, fasted 
levels. 
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Figure 22. Quantitative real-time PCR analysis of hepatic Fgf21 mRNA levels in 
CrebH-null, Pparα-null, and wild-type control mice under fed and fasting conditions 
with and without adenoviral rescue procedure. (A) Fgf21 levels in WT and Pparα-null 
mice under fed and fasting conditions. Additional Pparα-null mice were treated with 
adenovirus expressing GFP or CrebH, and Fgf21 mRNA levels were assessed. (B) 
Fgf21 levels in WT and CrebH-null mice under fed and fasting conditions. Additional 
CrebH-null mice were treated with adenovirus expressing GFP or Pparα, and Fgf21 
mRNA levels were assessed. Fold changes of mRNA expression levels were 
calculated after normalization to that of β-actin. Bars denote mean values ± SEM 
(n=3). * p≤ 0.05; p ≤ 0.01. 
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Figure 23. Western Blot analysis of serum FGF21 protein levels in CrebH- and 
Pparα-null mice under fed or fasting conditions with and without adenoviral rescue 
procedure. (A) FGF21 protein levels in WT and Pparα-null mice under fed and fasting 
conditions. Additional Pparα-null mice were treated with adenovirus expressing GFP 
or CrebH, and FGF21 protein levels were assessed by Western blot analysis. (B) 
FGF21 protein levels in WT and CrebH-null mice under fed and fasting conditions. 
Additional CrebH-null mice were treated with adenovirus expressing GFP or Pparα, 
and FGF21 protein levels were assessed. Serum albumin protein levels were 
determined as loading controls. 
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The capability of PPARα and CREBH to bind to the promoter region of the 
Fgf21 gene was determined in order to evaluate the proteins as possible initiators of 
Fgf21 gene transcription. DNA-protein binding was activity assessed via ChIP assay 
(Figure 24A). Huh7 cells were infected with adenovirus-expressing GFP, active 
CrebH, Pparα, or a combination of active CrebH and Pparα. PCR was performed on 
the precipitate product using primers targeting the Fgf21 gene promoter region 
(Appendix B). Protein-DNA binding complexes in Huh7 cells expressing CrebH, 
Pparα or a combination of the two were pulled-down using anti-PPARα or anti-
CREBH antibodies and subjected to ChIP-PCR amplification of the Fgf21 gene 
promoter region containing the CRE-PPRE binding elements (Appendix B). The 
ChIP-PCR results showed that CREBH and PPARα can bind to the Fgf21 gene 
promoter (Figure 24A). Interestingly, co-expression of CREBH and PPARα yielded 
stronger binding activity to the Fgf21 promoter than expression of either CREBH or 
PPARα, thus confirming the synergistic effect of CREBH and PPARα on driving 
Fgf21 gene transcription. As a control, expression of GFP yielded negative results 
with PPARα and CREBH pull-down. 
Because the cAMP response element is a binding site for multiple members of 
the CREB protein family, we tested the specificity of the element for CREBH binding 
via ChIP assay (Figure 24B). Huh7 cells were infected with plasmid expressing Creb1 
or CrebH or an empty vector. Pull-down was performed with cells over-expressing 
Creb1 or vector control using anti-CREB and anti-CREBH antibodies. PCR was used 
to amplify the same Fgf21 promoter sequence as the previous experiment. Pull-down 
using anti-CREB antibodies failed to produce positive Fgf21 promoter-binding signals 
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(Figure 24B), suggesting that it is CREBH, not CREB, that binds to the proximal 
Fgf21 gene promoter. 
 
 
Figure 24. ChIP assay for CREBH, PPARα, and CREB binding activities at the 
human FGF21 gene promoter region. (A) ChIP with Huh7 cells infected with 
adenovirus expressing GFP CrebH, Pparα, or an equal-titer combination of CrebH 
and Pparα. PCR was used to amplify the target sequence on the Fgf21 promoter 
region containing the CRE-PPRE consensus sequence (Appendix B). Input used as 
positive control. Negative controls include the Huh7 cells with GFP overexpression, 
no antibody pull-down, IgG antibody pull-down, and PCR using primers targeting the 
FUT1 gene. (B) ChIP using Huh7 cells transfected with plasmid expressing CREB or 
CREBH or empty vector. PCR was used to amplify the target sequence on the Fgf21 
promoter region. Input used as positive control. Negative controls include empty 
vector transfection, no antibody pull-down, IgG antibody pull-down, and PCR using 
primers targeting the FUT1 gene. An additional positive control was included for 
CREB-transfected cells. In this control, PCR was performed using primers targeting 
the promoter region of the known CREB target, Pck1. 
57 
   
 
To identify interactions between CREBH and PPARα immunoprecipitation (IP) 
Western blotting analyses were performed with liver tissue samples from mice under 
fasting or after AHF diet feeding (Figure 25). Liver tissues from wild-type mice under 
normal chow feeding, 14-hour overnight fasting, or after 6-month AHF diet feeding 
were homogenized and protein was isolated. Pull-down was performed with the anti-
CREBH or anti-PPARα antibody. Pull-down fraction and whole lysate were analyzed 
by Western blot and probed with the anti-CREBH or anti-PPARα antibody. Western 
blot showed the interaction between PPARα and CREBH that is particularly favored 
under the fasting or AHF diet-fed condition. 
 
Figure 25. Immunoprecipation of liver protein lysates from wild-type mice under 
metabolic stress. Liver lysate from wild-type mice under normal chow, fasting, or AHF 
diet feeding. Precipitation was induced by pull-down with the anti-PPARα or anti-
CREBH antibody. Pull-down fractions and whole lysate were probed with the PPARα 
or CREBH antibody. Levels of β-actin in the total lysates were determined as loading 
controls. 
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3.4 Discussion 
Owing to the potential of Fgf21 as a key component of CREBH metabolic 
control, we sought to define the relationship underlying this regulation and its 
mechanism. This resulted in the discovery of the conserved and adjacent CRE and 
PPRE-1/2 elements on the promoter region of the Fgf21 gene (figure 14). The 
conserved nature of the elements marks them as potentially integral for proper 
expression of Fgf21. The proximity of these elements indicates that a PPAR protein 
family member may be functioning as a binding partner for CREBH during Fgf21 
induction. A previous study had revealed that, under an AHF-diet, CREBH up-
regulates Pparα expression. Figures 20 and 21 showed the shared regulatory pattern 
of CrebH- and Pparα-null mice under feeding and fasting conditions. These analyses 
also identify PPARα as a mediator of fasting-induced Fgf21 up-regulation.  
In order to determine the importance of the CRE and PPRE1/2 elements in 
Fgf21 expression, we carried out a reporter assay using the wild-type Fgf21 gene 
promoter and its mutant isoforms (FM13, PE-M1, PE-M2, and PE-M12). The FM 
promoter with the site mutation in the CRE binding element was unable to produce 
reporter activity under CREBH overexpression conditions (Figure 17). This shows the 
importance of the CRE element. Indirectly, this indicates that Fgf21 expression is 
highly dependent on CREBH. The reporter activity linked to the PE-M1 promoter with 
the site mutation in one of the PPRE binding elements in the Fgf21 gene promoter 
was similar to that of the wild-type promoter in all testing conditions (Figures 16 and 
17). Additionally, reporter activities driven by the PE-M2, which harbors a site 
mutation at the second PPRE binding element in the Fgf21 gene promoter, and PE-
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M12, in which both PPRE elements were mutated, were similar in all overexpression 
conditions and both were lower than that of the wild-type promoter. This leads us to 
the conclusion that PPRE1 does not play a role in CREBH- or PPARα-dependent 
Fgf21 upregulation, but PPRE2 does play a role in this regulation. Due to the higher 
level of reporter activity in cells that co-expressed Pparα and CrebH, compared to 
expression of Pparα or CrebH alone, it is clear that both proteins are required to 
reach proper levels of Fgf21 expression. 
The next step of our study was to determine the individual contributions of 
CREBH and PPARα as inducers of Fgf21. We attempted to rescue Fgf21 expression 
in both CrebH- and Pparα-null mice with Pparα and CrebH overexpression, 
respectively (Figures 22 & 23). The results of this experiment showed that, while both 
PPARα and CREBH play a role in the regulation of Fgf21, exogenous expression of 
CREBH alone is sufficient to induce Fgf21 transcription, but PPARα requires 
interaction with CrebH to accomplish the same result. 
In Figure 25, we showed that inducing metabolic stress by fasting or AHF diet 
results in interaction between CREBH and PPARα. This indicates the existence of a 
CREBH-PPARα complex under metabolic stress. By employing ChIP analyses, we 
were able to show direct binding of the CREBH-PPARα complex to the Fgf21 
promoter (Figure 24). We were also able to show that the CRE binding site on the 
promoter is specific to CREBH. This leads us to conclude that PPARα interacts and 
forms a complex with CREBH under metabolic stress, such as fasting or AHF diet-
feeding. This complex binds to the CRE and PPRE1/2 elements of the Fgf21 
promoter region and initiates Fgf21 transcription. The transcriptional upregulation 
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results in increased FGF21 protein content in mouse liver and serum under fasting 
conditions (Figures 13 and 20).  
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CHAPTER IV: Exogenous FGF21 Administration Rescues CrebH-
null Phenotype 
 
4.1 Summary 
 CrebH-null mice are susceptible to AHF diet-induced NAFLD and NASH. 
FGF21, a transcriptional target of CREBH, has proven to be a potent treatment option 
for these diseases. In this chapter, we describe the rescue of the NASH phenotype of 
CrebH-null mice developed under the AHF diet by injections of recombinant human 
FGF21 protein. Treatment with recombinant protein was an effective method of 
increasing serum FGF21 protein levels and decreasing body weight in CrebH-null 
mice when compared to vehicle control. Injection of FGF21 improved hyperlipidemia, 
hypoketonemia, hepatic steatosis, hepatocyte ballooning, and hepatomegaly. 
Additionally, glucose tolerance was improved in AHF diet-fed CrebH-null mice upon 
FGF21 protein treatment. The success of this treatment in rescuing the AHF diet-fed 
CrebH-null mouse disease phenotype indicates the importance of FGF21 in the 
CREBH-regulated metabolic stress response. Furthermore, effectiveness of the 
treatment puts FGF21 forward as a potential exciting therapeutic option for 
hypertriglyceridemia and NASH. 
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4.2 Materials and Methods 
Materials  
Synthetic oligonucleotides were purchased from Integrated DNA 
Technologies, Inc. (Coralville, IA). The crude blood serum antibody was purified 
through affinity purification. Kits for measuring TG, FA, and ketone body 3-
hydroxybutyric acid were from BioAssay Systems (Hayward, CA). Purified, bioactive 
recombinant human FGF21 protein was purchased from ProSpec-Tany TechnoGene 
Ltd (Ness Ziona, Israel). Mouse monoclonal anti-FGF21 antibody and FGF21 ELISA 
kit were from R & D Systems, Inc. (Minneapolis, MN). OneTouch Ultra glucometer 
and blood glucose measurement strips were purchase form Johnson & Johnson, Inc. 
Animal experiments 
For the FGF21 rescue animal experiment, daily injections of purified, bioactive 
rhFGF21 protein and control injections of vehicle (sterile water) were carried out for 8 
days. CrebH-null and wild-type control male mice after the AHF diet for 6 months 
were injected i.p. with 0.1 g purified recombinant human FGF21 protein per gram 
body weight or the vehicle PBS. On the fifth day of injection, mice were fasted for 12 
hours. Following fasting, on the sixth day of injection, glucose tolerance tests were 
performed. Mice were allowed to recover for 2 days with ongoing injections before 
they were euthanized and tissues were harvested. All the animal experiments were 
approved by the Wayne State University IACUC committee and carried out under the 
institutional guidelines for ethical animal use. 
 
63 
   
 
Measurement of mouse lipid metabolites 
Liver tissue and blood plasma samples were isolated from the mice under the 
normal chow diet, after fasting, or after the AHF diet. To determine hepatic TG levels, 
approximately 100 mg liver tissue was homogenized in 500 μl PBS followed by 
centrifugation at 10K r.p.m for 5 min. The supernatant was mixed with 500 μl 10% 
Triton-100 in PBS for TG measurement using a commercial kit (BioAssay Systems, 
CA). Mouse hepatic TG levels were determined by normalization to liver tissue mass 
used for TG measurement. Mouse blood plasma samples were subjected to 
quantitative analyses of TG, free FA, and the ketone body metabolite 3-
hydroxybutyric acid using the commercial kits (BioAssay Systems). 
Oil-red O staining 
Frozen liver tissue sections were stained with Oil-red O for lipid contents 
according to standard protocol (107). Briefly, frozen liver tissue sections of 8 microns 
were air-dried, and then fixed in formalin. The fixed sections were rinsed with 60% 
isopropanol before they were stained with freshly prepared Oil-red O solution for 15 
minutes. After Oil-red O staining, liver sections were rinsed again with 60% isopropanol 
followed by washing with water before subjected to microscope analysis. 
Sirius-red staining of hepatic collagens  
Sirius-red staining of collagen deposition in liver tissue section for fibrosis 
evaluation was as previously described (107). Briefly, paraffin-embedded mouse liver 
tissue sections (5μm) were pretreated with xylene, ethanol, and water according to 
the standard protocol. The liver tissue sections were stained for 1 hr with Sirius red 
solution (Sigma) and then washed with acidified water (0.5% acetic acid). The stained 
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tissue sections were dehydrated with 100% ethanol and cleared in xylene before 
being mounted with mounting solution. 
GTT assay 
Glucose tolerance tests of the CrebH-null and wild-type control mice after 6 
days of administration of the FGF21 protein or vehicle. Animals were fasted for 12 
hours before infused with 1 mg D-glucose per gram body weight. Blood glucose 
levels were measured from tail blood using an OneTouch Ultra glucometer (Johnson 
& Johnson). 
Statistics  
Experimental results are shown as mean ± SEM (for variation between 
animals or experiments). All in vitro experiments were repeated with biological 
triplicates at least three times independently. Mean values for biochemical data from 
the experimental groups were compared by paired or unpaired, 2-tailed Student’s t 
tests. Multiple comparisons were compared with ANOVA and proceeded by ad hoc 
statistical test when necessary. Statistical tests with P < 0.05 were considered 
significant. 
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4.3 Results 
In order to determine whether Fgf21 is the major target of CREBH in regulating 
lipid metabolism and to evaluate the potential effect of FGF21 on reversing the NASH 
phenotype resulting from CrebH deletion, we fed the AHF diet to CrebH-null mice to 
establish the NASH disease model.  
 
Figure 26. Effects of administration of recombinant FGF21 protein on serum FGF21 
levels and body weights. (A) CrebH-null mice showed increased circulating levels of 
FGF21 upon FGF21 protein administration. (B) FGF21 protein administration induced 
a modest but significant decrease in body weight compared to the vehicle control. 
Each bar denotes the mean ± SEM (n=5 mice treated with vehicle and 4 mice treated 
with FGF21). * P≤0.05. 
 
We administered a series of recombinant human FGF21 protein injections to 
CrebH-null mice after the AHF diet. FGF21 protein was administered by 
intraperitoneal injection daily for 8 days. Effectiveness of FGF21 protein 
administration was assessed by FGF21 serum concentration after the series of 
injections in CrebH-null mice (Figure 26). FGF21 protein administration successfully 
increased circulating FGF21 protein levels. Additionally, since long term FGF21 
protein administration has been shown to induce weight loss in mice, mouse body 
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weight was measured upon the 8-day administration of FGF21 protein (82, 84). 
Protein injection was accompanied by small but significant decrease in body weight 
for the FGF21-injected mice (Figure 26).  
 
  
Figure 27. Infusion of recombinant FGF21 protein reverses hypertriglyceridemia, and 
hypoketonemia in CrebH-null mice after the AHF diet. CrebH-null (KO) and wild-type 
(WT) control mice were fed with AHF diet for 6 months before they were injected i.p. 
with purified recombinant FGF21protein or vehicle once a day for 8 days. Levels of 
serum TG (A), ketone body BOH (B), and FA (C) in the WT and CrebH-null mice 
administrated with recombinant FGF21 protein or vehicle (Veh). The blood samples 
were collected from the mice after 12-hour fasting on the sixth day of administration 
of FGF21 protein or vehicle. Each bar denotes the mean ± SEM (n = 5 WT or KO 
mice treated with vehicle and 4 KO mice treated with FGF21). *, p ≤ .05; **, P ≤ 0.01. 
 
To determine the ability of FGF21 to rescue metabolic syndrome in AHF diet-
fed CrebH-null mice, wild-type and CrebH-null mice were fed an AHF-diet for 6 
months. After the feeding period, CrebH-null mice were administered either FGF21 
protein or vehicle control (PBS). Wild-type mice were given vehicle control only. 
CrebH-null mice that received FGF21 injection showed improved lipid metabolite 
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profiles and liver pathological states compared to vehicle-injected CrebH-null mice 
controls (Figure 27). Vehicle-injected control CrebH-null mice exhibit increased TG 
and free FA levels in serum that indicate onset of NAFLD and metabolic syndrome. 
Additionally, serum ketone levels were reduced compared to wild-type controls. In 
contrast, FGF21-injected mice showed comparable levels of serum TG and free FA 
to wild-type controls. These mice also showed increased serum ketone levels 
compared to both wild-type and CrebH-null mice with vehicle treatment. These 
results indicate that FGF21 is the major downstream factor targeted by CREBH in 
regulating TG and FA metabolism. This also shows that the capacity of FGF21 to 
treat hyperlipidemia extends to diseases that are caused by CREBH deficiency. 
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Figure 28. Infusion of recombinant FGF21 protein partially rescued NASH phenotype 
of the CrebH-null mice after the AHF diet. CrebH-null (KO) and wild-type (WT) control 
mice were fed with AHF diet for 6 months before they were injected i.p. with purified 
recombinant FGF21protein or vehicle once a day for 8 days. Histologic staining 
analysis of liver tissue sections from the wild-type and CrebH-null mice after 8 days of 
FGF21 protein or vehicle treatment. (A) Oil-red O staining of hepatic lipid droplets. (B) 
Hematoxylin and eosin (HE) staining of liver tissue sections. (C) Sirius red staining of 
hepatic collagens. Magnification: 200x. 
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FGF21 protein injection was also able to rescue hepatic symptoms of NASH. 
Oil Red O staining of lipid droplets in liver tissue showed that the AHF-diet regimen 
was successful in inducing NAFLD in vehicle-treated CrebH-null mice (Figure 28A). 
This effect was ameliorated CrebH-null mice that were injected with FGF21 protein. 
Enzymatic analysis of liver TG levels confirmed reduced TG content in FGF21-
injected CrebH-null mice (Figure 29A). Hepatocyte ballooning was reduced in CrebH-
null mice after FGF21 treatment, as well (Figure 28B). This was corroborated by a 
significant decrease in hepatocyte size (Figure 29B). Portal and lobular inflammation 
were unaffected by FGF21 treatment CrebH-null mice (Figure 28B). Fibrosis 
(assessed by Sirius Red staining of collagen) was not decreased in these mice, either 
(Figure 28C). The long-term stress caused by AHF diet-feeding (6 months) may have 
caused morphological changes that were unable to be overcome by the relatively 
short treatment period (8 days). Effects of FGF21 injection were detectable from a 
gross anatomical observation (Figure 30). CrebH-null mice that received FGF21 
treatment displayed improved liver size and coloration compared to vehicle-injected 
CrebH-null mice. Additionally, FGF21, as a potent metabolic hormone, modulates 
lipid metabolism in adipose tissues (110-112). 
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Figure 29. Administration of recombinant FGF21 protein reverses hepatic steatosis 
phenotype developed in the CrebH-null mice under the AHF diet. (A) Levels of 
hepatic TG in the livers of the wild-type (WT) and CrebH-null mice treated with 
recombinant FGF21 protein (FGF21) or vehicle. (B) Fold change of hepatocyte sizes 
in the livers of the wild-type and CrebH-null mice administrated with recombinant 
FGF21 protein or vehicle. For the tissue section from each animal, sizes of 
hepatocytes from 3 representative tissue areas per mouse were calculated to obtain 
the average hepatocyte size for each treatment group. Each bar denotes the mean ± 
SEM (n=5 WT or KO mice treated with vehicle and 4 KO mice treated with FGF21). * 
P ≤ 0.05. 
 
 
 
 
Figure 30. Gross anatomical inspection of liver morphology after FGF21 protein 
administration.  
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Because NASH typically presents with glucose intolerance and insulin 
resistance, we assessed the effect of FGF21 protein injection on the improvement of 
glucose tolerance in CrebH-null mice (64). GTT was performed and indicated 
improved glucose tolerance in CrebH-null mice injected with FGF21 compared to 
CrebH-null mice injected with vehicle control (Figure 31). These results not only 
confirm that FGF21 is the major CREBH-target in regulating lipid metabolism, but 
also indicate that FGF21 protein administration may be an effective treatment to 
rescue NASH and its related metabolic symptoms. 
 
 
Figure 31. GTT analysis with CrebH-null (KO) and wild-type (WT) control mice after 
administration with vehicle PBS or FGF21 protein. KO and WT control mice were fed 
with AHF diet for 6 months before they were injected i.p. with purified recombinant 
FGF21protein or vehicle once a day for 6 days. Mice were subjected to fasting blood 
sample collection and glucose tolerance test after 12-hour fasting Glucose tolerance 
tests of the CrebH-null and wild-type control mice after administration of the FGF21 
protein or vehicle. Animals were fasted for 12 hours before being infused with 1 mg 
D-glucose per gram body weight. Each bar denotes the mean ± SEM (n = 5 WT or 
KO mice treated with vehicle and 4 KO mice treated with FGF21). 
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4.4 Discussion 
Having characterized the molecular mechanism by which CREBH regulates 
Fgf21 expression, we sought to delineate the functional impact of the CREBH-FGF21 
regulatory axis in lipid homeostasis and metabolic disorders. CrebH-null mice 
develop profound hyperlipidemia and NASH under the AHF diet (Figure 5) (12). 
Therefore, the AHF-fed CrebH-null animal model is a perfect model system for 
evaluating therapeutic potential of FGF21 protein treatment in metabolic symptoms 
associated with impaired lipid metabolism. Through administration of recombinant 
FGF21 protein to the CrebH-null mice, we demonstrated the effects of FGF21 
treatment in decreasing blood TG and FA of the CrebH-null mice (Figure 27). FGF21 
treatment can partially rescue hepatic inflammation and fibrosis in the CrebH-null 
mice after the AHF diet (Figures 28 and 29). These results confirm that FGF21 is a 
major target of CREBH in regulating lipid homeostasis under metabolic stress.  Our 
findings also identify FGF21 as a potential therapeutic agent in the treatment of 
NASH.  
The significance of these findings is also implicated by the fact that the 
transcriptional regulation of Fgf21 by CREBH that we have outlined is reflected at the 
physiological level. The CREBH-dependent increase in serum FGF21 levels coupled 
with the ability of circulating FGF21 to induce signaling at a systemic level opens up 
the possibility that CREBH may have a more direct role in modulating metabolism 
outside of the liver. 
CrebH-null mice are susceptible to diet-induced NASH. FGF21 has been 
shown to rescue metabolic disorders in diet-induced disease models. We performed 
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similar experiments using our CrebH-null model of NASH. Previous reports of FGF21 
protein injection experiments indicate that this procedure induced significant weight 
loss in mice that have been fed a high-fat diet. In our study, administration of FGF21 
protein to the CrebH-null mice for 8 days led to a modest loss in body weight (Figure 
26B). This is likely due to the relatively short time frame of the treatment over which 
the experiment was carried out. It is likely that a more sustained regimen would 
produce more drastic weight loss in our mouse model. To further support the 
effectiveness of the treatment, serum FGF21 levels radically increased in mice that 
received the rescue treatment (Figure 26A). The ability of the FGF21 treatment to 
rescue the hyperlipidemia and hepatocyte size increase present in the CrebH-null 
disease model mice implicates that CREBH can significantly mediate hepatic 
metabolic state by modulating Fgf21 expression. 
The effectiveness of the treatment in reversing the hyperlipidemia associated 
with our model shows that these effects can reach the circulating serum and have 
systemic effects. Functional mutations in CREBH have already been identified as a 
contributing factor in hypertriglyceridemia in human patients (70). FGF21 is currently 
a topic of interest as a therapeutic option. The findings from my rescue experiment 
confirm the pleiotropic effects of exogenous FGF21 administration on lipid 
metabolism and its promising therapeutic potential in metabolic disorders. Our study 
offers important evidence for FGF21 as a potential treatment option for patients 
suffering from hypertriglyceridemia linked to CREBH mutation.  
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CHAPTER V: Conclusions and Significance 
 CREBH is emerging as a key player in hepatic response to metabolic stress. 
This work identifies the phenotypic effect of CrebH deficiency under various 
metabolic stress conditions. Previous studies suggested a major role for CREBH in 
lipid metabolism and gluconeogenesis under high-fat diet-induced stress. However, 
the method by which CREBH regulates complex metabolic programs involved in 
multiple pathways under metabolic stress remains elusive. My studies established 
that CREBH plays this role under fasting-induced stress and that the length of the 
fast affects the regulation. Additionally, it was demonstrated that CREBH regulates 
ketogenesis by targeting Bdh1 and Hmgcs2. Importantly, Fgf21 was identified as a 
target of CREBH. Because of the importance of FGF21 as a metabolic hormone, we 
focused our attention on defining the mechanism of this regulation. At the molecular 
lever, CREBH interacts with PPARα to activate FGF21 expression through a multi-
layered regulatory mechanism. CREBH and PPARα regulate each other at the 
transcriptional level in liver upon metabolic stress, such fasting or AHF diet (Figure 20 
and 21). Metabolic stress-induced expression of Fgf21 requires both CREBH and 
PPARα. The coordination between CREBH and PPARα in regulating Fgf21 
expression involves protein-protein interaction during fasting or AHF diet-feeding 
(Figure 25). Inspection of the Fgf21 promoter led to the recognition of the juxtaposed 
CRE and PPRE binding sites where CREBH and PPARα are enriched under 
metabolic stress (Figure 15). Through protein-protein and protein-DNA interactions, 
CREBH and PPARα function in synergy to activate expression of the Fgf21 gene. 
CREBH and PPARα appear to act as binary trans-activators that regulate each other 
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for their expression and interact with each other for their function. In the future, 
understanding how CREBH interacts with other proteins to modify its transcriptional 
effects will be key to understanding the regulatory mechanism of CREBH in stress 
response. 
An important part of my work is the demonstration of the therapeutic potential 
of FGF21 in the treatment of NASH and its common comorbidities. By administering 
the AHF diet to CrebH-null mice, previous studies in our lab have generated a 
disease model of NASH that is dependent on CREBH deficiency (12). CrebH-null 
mice develop profound hypertriglyceridemia, hypoketonemia, and NASH under the 
AHF diet. Therefore, the AHF-fed CrebH-null mouse is a perfect model system for 
evaluating the therapeutic potential of FGF21 protein as a treatment option in NASH 
and its associated symptoms. Owing to the severity of NASH and associated 
metabolic dysfunction, as well as the increasing interest in FGF21 as a therapeutic 
option, we chose to treat our disease model mice using recombinant human FGF21 
protein. CrebH-null mice showed a partial recovery from the NASH state in response 
to this treatment. Previous studies have used exogenous FGF21 protein to treat 
metabolic disease model animals (82, 86). However, the effectiveness of FGF21 
protein in the treatment of NASH and CREBH-deficiency were novel findings. 
Because this treatment lowered serum TG levels and human CREBH deficient 
patients suffer from hypertriglyceridemia, this discovery is pertinent to the 
management of human disease. 
This body of work was created with the goal of understanding of the 
mechanism of CREBH regulatory action. Based on my findings, I can make three 
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conclusions that make strong headway in achieving this goal (Figure 32). First, 
CREBH is essential for hepatic adaptation to metabolic stress, particularly for the 
response involved in lipid metabolism. Second, FGF21 plays a role in mediating 
these effects and CREBH works in tandem with PPARα to promote Fgf21 expression. 
Third, the metabolic disease phenotype observed in CrebH-deficient mice under an 
AHF diet is relieved by exogenous FGF21 administration. Therefore, these findings 
extend the relationship between the nuclear receptors and ER-associated trans-
activators in regulating energy metabolism. 
However, my research does not fully describe the role of CREBH in metabolic 
regulation. Much work remains to be done in this field in order to meet that goal. Of 
particular importance is the role of CREBH in the regulation of metabolism under 
high-sucrose diet-induced stress. Fasting and high-fat diet-feeding activate some 
common response pathways, such as lipolysis and ketogenesis (113-116). High-
sucrose diet-feeding activates a distinct set of responses, including glycolysis and 
lipogenesis(117). The potential activation of CREBH by a stress factor that differs so 
fundamentally from previously described inducers greatly broadens the prospective 
range of CREBH-mediated metabolic control. Addressing these questions in the 
future will provide novel insights into the key transcriptional programs that control 
energy homeostasis and has important implications in the understanding and 
treatment of metabolic disease. 
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Figure 32. Proposed model of CREBH-mediated Fgf21 regulation. Under fasting or 
high-fat diet feeding conditions, CREBH associates with PPARα at the Fgf21 
promoter region under metabolic stress. Fgf21 is up-regulated at the RNA and protein 
levels. Lipid and ketone metabolism pathways are activated. The original metabolic 
stress is alleviated by the action of the CREBH-PPARα-FGF21 regulatory axis. 
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APPENDIX A 
 
 
 
Sequence information for primers used in quantitative real-time PCR studies. 
  
Gene name Forward primer  Reverse primer 
CrebH TCGTGCCAGTGCGAGTGT AGCCACGCGGGATGC 
PPARα GAAGGGCACACGCGTGCGAGTTTTCAG CTGTGATGACAACGTCTTGTTCCCGAACT 
Apoc2 CTCTGCTGGGCACGGTGCA GCCGCCGAGCTTTTGCTGTAC 
Apoa4 GCATCTAGCCCAGGAAACTG ATGTATGGGGTCAGCTGGAG 
Fgf21 GTGTCAAAGCCTCTAGGTTTCTT  GGTACACATTGTAACCGTCCTC 
ApoA5 TCCTCGCAGTGTTCGCAAG GAAGCTGCCTTTCAGGTTCTC 
Bdh1 TGACACCCGTCGGACCTAC TTCTCAGTCGGTCACTCTTCA 
Hmgcs2 GAAGAGAGCGATGCAGGAAAC GTCCACATATTGGGCTGGAAA 
Ldha TGTCTCCAGCAAAGACTACTGT GACTGTACTTGACAATGTTGGGA 
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APPENDIX B 
Human FGF21 Promoter 
 
     1 CGAGTGGAGC GATCGTCCGC CCTCTGCCGC GTCCTCCTGG GGGATGGAGA ACCTGTTTGC 
    61 CAGGCTGCCG CCGGAGCGCG CGAGGGCCTC CAGCCTGCAG GTGCTCCCGC GCCCACCAGG 
   121 GTCTCCGATC TCCCACACCC CCCGCCTCAC CGTCCACACT CAAATTCCAG AATCCCAGCC 
   181 CCTAGTCACT CCTTTTGGGG AATTCTAGGG TCCCGTGCCA AACTGCTACT TTCCAGACCT 
   241 GCACTGCACG AAGGCAACCA TTCCAAGGCT GGAGACCGGA GTGGAACAGG GTCTGTTTCC 
   301 CACGCCGTCA GCGGGGGCCG TGGCTGCCGG CGCCAGAGAC AAAGGCCTCT GCCCGCTTGT 
   361 CACCTAATTA AAGCATTTTC TCTGGTCCAA GGCCCACCTC CAGCATCGCC AACCCCGAGC 
                                 CAGGTT CCGGGTGGAG GTCGT 
   421 AGGGCAGGCT AACGTAGGGT CCAGCCCTAC GGGGCTTTGC GGGTGGGTGT TCTTCCCCTG 
   481 TGAGGAGAGG AGAGATTGTA AGAAATAAAG ACACAAGACA AAGAGATAAA GAGAAAACAG 
   541 CTGGGCCCGG GGGACCACTA CCATCAAGAC GCAGAGACCG GTAGTGGCCC CGAATGGCTG 
     -----------------------------------------------------------------    
     ----------------------------------------------------------------- 
   2641 AGATGGTCCA AGAGGTGGTT TTTCCAGGAG CCCAGCACCC CTCCTCCCTC CGACTCAGGT 
   2701 GCTTGAGACC CCAGATCCTT CTCTCTGAGA CTCAGGAATG TGGGCCCCCA GCCCCTTTCA 
   2761 CCTGGGTCCC AGCTAACCCG ATCCTCCCCT CCCTCATCCC CTAGACCCAG GAGTCTGGCC 
   2821 CTCCATTGAA AGGACCCCAG GTTACATCAT CCATTCAGGC TGCCCTTGCC ACGATGGAAT 
   2881 TCTGTAGCTC CTGCCAAATG GGTCAAATAT CATGGTTCAG GCGCAGGGAG GGTGATTGGG 
 
   2941 CGGGCCTGTC TGGGTATAAA TTCTGGAGCT TCTGCATCTA TCCCAAAAAA CAAGGGTGTT 
   3001 CTGTCAGCTG AGGATCCAGC CGAAAGAGGA GCCAGGCACT CAGGCCACCT GAGTCTACTC 
                           CG GCTTTCTCCT CGGTCCG 
   3061 ACCTGGACAA CTGGAATCTG GCACCAATTC TAAACCACTC AGCTTCTCCG AGCTCACACC 
       CDS 
   3121 CCGGAGATCA CCTGAGGACC CGAGCCATTG ATGGACTCGG ACGAGACCGG GTTCGAGCAC 
   3181 TCAGGACTGT GGGTTTCTGT GCTGGCTGGT CTTCTGCTGG GAGCCTGCCA GGCACACCCC 
   3241 ATCCCTGACT CCAGTCCTCT CCTGCAATTC GGGGGCCAAG TCCGGCAGCG GTACCTCTAC 
   3301 ACAGATGATG CCCAGCAGAC AGAAGCCCAC CTGGAGATCA GGGAGGATGG GACGGTGGGG 
   3361 GGCGCTGCTG ACCAGAGCCC CGAAAGTGAG TGTGGGCCAG AGCCTGGGTC TGAGGGAGGA 
   3421 GGGGCTGTGG GTCTGGATTC CTGGGTCTGA GGGAGGAGGG GCTGGGGGCC TTGGCCCCTG 
   3481 GGTCTGAGGG AGGAGGGGCT GGGGATCTGG ACTCCTGGGT CTGAGGGAGG AGGGGCTGGG 
   3541 GATCTGGGCC CCTGGGTCTG AGGGAGGAGG GGCTGGGTCT GGACCCCTGG GTCTGAGGGA 
   3601 GGAGGGGCTG GGGGTCTGGA CTCTTGGGTT TGAAGAAGGA AGGGCTGGGG TCCTGGACTC 
   3661 TTGGGTCTGA GTTGGGAGGG GGCTTTGGCT TGGGCTTCTC CTGGGTCTGA GGGAGGAGGT 
   3721 AGGCTGTGGG CTTGGACTCC CAGGGCTGGG ACAGAGCCGG ATGGTGGGAC AGAGTCGGGT 
   3781 GGTGGGACAG TCCCGGGTGG GAGAGGTCCT CGAACCACCT TATCGCTTTC ACCCCTTAGG 
   3841 TCTCCTGCAG CTGAAAGCCT TGAAGCCGGG AGTTATTCAA ATCTTGGGAG TCAAGACATC 
   3901 CAGGTTCCTG TGCCAGCGGC CAGATGGGGC CCTGTATGGA TCGGTGAGTT TCCAGGACCC 
   3961 TCCTCACCAC CCACCATGCT CCTCCTATAT GTCGCCCTCA C 
 
           hFGF21 ChIP (CREBH)-B 
           hFGF21 ChIP (NS)-B: ChIP negative control primers 
 
Sequence of the human FGF21 gene promoter highlighting potential CREBH and 
PPARα binding sites, FGF21 ChIP primers, and ChIP negative control primers. 
CREB PPRE1 PPRE2 
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ABSTRACT 
THE ROLE OF CREBH IN HEPATIC ENERGY REGULATION UNDER 
METABOLIC STRESS 
by 
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Degree: Doctor of Philosophy 
Lipid metabolism is tightly regulated by nuclear receptors, transcription factors, 
and cellular enzymes in response to nutritional, hormonal, and stress signals. 
Hepatocyte specific, cyclic AMP responsive element-binding protein (CREBH) is a 
transcription factor that is preferentially expressed in the liver and localized in the 
endoplasmic reticulum (ER) membrane. CREBH is known to be activated by ER 
stress, inflammatory stimuli, and metabolic signals to regulate hepatic acute-phase 
response, lipid metabolism, and glucose metabolism. In my thesis research, I have 
characterized the roles and mechanisms of CREBH in these functions, as well as the 
overall phenotype of CrebH-null mice. I demonstrated that CREBH interacts with 
peroxisome proliferator-activated receptor α (PPARα) to regulate expression of the 
genes involved in lipolysis, FA oxidation, and ketogenesis by activating fibroblast 
growth factor 21 (FGF21), a hepatic hormone that regulates whole-body energy 
homeostasis. Gain- and loss-of-function analyses indicated that CREBH and PPARα 
97 
   
 
regulate each other for their expression. Activated CREBH protein interacts with 
PPARα under fasting or metabolic diet, and both factors are required for induction of 
the FGF21 gene. CREBH and PPARα bind to integrated CREH-PPARα binding 
motifs in the FGF21 gene promoter across mammalian species. CREBH and PPARα 
function in synergy to activate the FGF21 gene promoter. Administration of 
recombinant human FGF21 protein can rescue hypertriglyceridemia and 
hypoketonemia and, partially, nonalcoholic steatohepatitis (NASH) in the CrebH-null 
mice developed under an atherogenic high-fat diet, corroborating the role of CREBH 
in regulating FGF21. In summary, my research demonstrated the transcriptional 
mechanism for CREBH in regulating lipid metabolism by activating FGF21. In 
particular, the functional interaction between CREBH and PPARα in regulating 
FGF21 may represent an important transcriptional coactivation mechanism in 
maintaining lipid homeostasis under metabolic stress. 
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